Document:

Exhibit
10.6

 

Certain
information identified by bracketed asterisks ([* * *]) has been omitted from this exhibit because it is both not material and
would be competitively harmful if publicly disclosed.

 

AMENDED
AND RESTATED AGREEMENT

 

THIS
AMENDED AND RESTATED AGREEMENT (this “Restated Agreement”) is entered into as of February 18, 2019 (the
“Restatement Date”), between EYEMAX LLC, a Massachusetts limited liability company (“Eyemax”),
with a place of business at 74 Chestnut Street, Weston, Massachusetts 02493, and ETON PHARMACEUTICALS, INC., a Delaware
corporation (“Eton”), with a place of business at 21925 Field Pkwy, Suite 235, Deer Park, Illinois 60010.

 

RECITALS

 

Article
I —WHEREAS, Eyemax and Eton are parties to that certain Exclusive Sales and Marketing Agreement dated August 11, 2017 (the
“2017 Agreement”), pursuant to which, among other things, Eyemax granted Eton an exclusive right and license
to develop, manufacture and commercialize Products in the Territory (as such terms are defined herein);

 

Article
II —

 

WHEREAS,
Eton proposes to enter into a transaction with a Third Party pursuant to which Eton would convey (whether by license, sale
of assets, or a combination thereof) to such Third Party substantially all of Eton’s rights to develop, manufacture and
commercialize Products in the Territory (as more fully defined herein, the “Product Transaction”);

 

WHEREAS,
in order to facilitate such transaction, Eyemax desires to sell, convey, transfer, assign and deliver to Eton, and Eton desires
to purchase and acquire from Eyemax; all of Eyemax’s right, title and interest in and to all of the Purchased Assets (the
“Acquisition”); in each case, on the terms and subject to the conditions set forth herein; and

 

WHEREAS,
the effectiveness of the Acquisition shall be conditioned upon the consummation of the Product Transaction.

 

    	 	1	 

    	 

    

 

AGREEMENT

 

Article
III —NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Eyemax and Eton hereby agree as follows:

 

Article
IV —

 

1.
Definitions. For the purposes of this Restated Agreement, the following terms shall have the respective meanings set forth
below, and grammatical variations of such terms shall have corresponding meanings:

 

1.1
“Acquisition” shall have the meaning provided in the Recitals to this Restated Agreement.

 

1.2
“Acquisition Transaction” shall have the meaning provided in Section 5.8.

 

1.3
“Affiliate” shall mean, with respect to any Person, any other Person which directly or indirectly controls,
is controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if
it owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or other ownership interest of
the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies
of the other Person by any means whatsoever.

 

1.4
“Ancillary Agreements” shall mean the Bill of Sale, the General Assignment and Assumption Agreement and the
IP Assignment Agreement.

 

1.5
“Assumed Liabilities” shall have the meaning provided in Section 2.2.

 

1.6
“Bill of Sale” shall have the meaning provided in Section 2.6.1(i).

 

1.7
“Calendar Quarter” means a calendar quarter ending on the last day of March, June, September, or December.

 

1.8
“Cap” shall have the meaning provided in Section 8.6.2.

 

1.9
“Closing” shall have the meaning provided in Section 2.3.

 

1.10
“Closing Date” shall have the meaning provided in Section 2.3.

 

1.11
“Competing Business” shall have the meaning provided in Section 5.8.

 

1.12
“Confidential Information” shall have the meaning provided in Section 5.2.1.

 

1.13
“Eton Fundamental Representations” shall have the meaning provided in Section 8.1.2.

 

    	 	2	 

    	 

    

 

1.14
“Eton Indemnitees” shall have the meaning provided in Section 8.2.

 

1.15
“[* * *]” shall mean [* * *], a company organized under the laws of France.

 

1.16
“[* * *] Agreement” shall mean that certain [* * *] Agreement
between Eyemax and [* * *] dated [* * *], as amended to date.

 

1.17
“[* * *] Consent” shall have the meaning provided in Section 2.6.1(iv).

 

1.18
“Excluded Liabilities” shall have the meaning provided in Section 2.2.

 

1.19
“Excluded Transaction” shall mean, with respect to Eton:

 

1.19.1
completion of a merger, reorganization, amalgamation, arrangement, share exchange, consolidation, tender or exchange offer, private
purchase, business combination, recapitalization or other transaction involving Eton, as a result of which either (a) the stockholders
of Eton immediately preceding such transaction hold less than 50% of the outstanding shares, or less than 50% of the outstanding
voting power, respectively, of the ultimate company or entity resulting from such transaction immediately after consummation thereof
(including a company or entity which as a result of such transaction owns the then outstanding securities of Eton or all or substantially
all of Eton’ s assets, including, without limitation, Eton’s assets related to Products, either directly or through
one or more subsidiaries), or (b) any single Third Party Person or group (within the meaning of the U.S. Securities Exchange Act
of 1934 and the rules of the SEC thereunder as in effect, referred to as a “Group”) holds 50% or more of the
outstanding shares or voting power of the ultimate company or entity resulting from such transaction immediately after the consummation
thereof (including a company or entity which as a result of such transaction owns the then outstanding securities of Eton or all
or substantially all of Eton’s assets either directly or through one or more subsidiaries);

 

    	 	3	 

    	 

    

 

1.19.2
the direct or indirect acquisition (including by means of a tender offer or an exchange offer) by any Third Party Person or Group
of beneficial ownership (within the meaning of the U.S. Securities Exchange Act of 1934 and the rules of the SEC thereunder as
in effect), or the right to acquire beneficial ownership, or formation of any Third Party Group which beneficially owns or has
the right to acquire beneficial ownership, of 50% or more of either the outstanding securities of Eton power or the then outstanding
voting power of Eton, in each case on a fully diluted basis;

 

1.19.3
the sale or disposition to a Third Party of assets or businesses that constitute 50% or more of the total revenue or assets of
Eton (determined on a consolidated basis), including Eton’s assets or business related to Products; or

 

1.19.4
the sale of debt or equity securities of Eton in a bona fide financing transaction (in one or more closings) to one or more arm’s-length
financial investors.

 

1.20
“Eyemax Fundamental Representations” shall have the meaning provided in Section 8.1.1.

 

1.21
“Eyemax Indemnitees” shall have the meaning provided in Section 8.3.

 

1.22
“Eyemax IP Rights” shall mean, collectively, the Eyemax Patent Rights, the Eyemax Know-How Rights and the Eyemax
Registrations.

 

1.23
“Eyemax Know-How Rights” shall mean all trade secrets, clinical data and other knowhow rights in which Eyemax
or its Affiliates heretofore or hereafter has an ownership or (sub)licensable interest, in and to the Technology.

 

1.24
“Eyemax Patent Rights” shall mean (a) all patents that claim or cover the Technology in which Eyemax or its
Affiliates heretofore or hereafter has an ownership or (sub)licensable interest, (b) all divisions, continuations, continuations-in-part,
that claim priority to, or common priority with, the patent applications described in clause (a) above or the patent applications
that resulted in the patents described in clause (a) above, and (c) all patents that have issued or in the future issue from any
of the foregoing patent applications, including utility models, design patents and certificates of invention, together with any
reissues, reexaminations, renewals, extensions or additions thereto.

 

1.25
“Eyemax Registrations” shall mean all Regulatory Filings and Regulatory Approvals (and applications therefor)
regarding Products in which Eyemax or its Affiliates heretofore or hereafter has an ownership or (sub)licensable interest, including
ANDA No. 208158.

 

1.26
“FDA” shall mean the Food and Drug Administration of the United States or any successor thereto.

 

    	 	4	 

    	 

    

 

1.27
“First Commercial Sale” shall mean, with respect to any Product, the first sale of such Product, for commercial
purposes, to a Third Party after receipt of all necessary Regulatory Approvals for such Product.

 

1.28
“First Commercial Sale Milestone Payment” shall have the meaning provided in Section 4.3.2.

 

1.29
“Force Majeure Event” shall mean an event, act, occurrence, condition, or state of facts, in each case outside
the reasonable control of a party, including acts of God; acts of any government; any rules, regulations, or orders issued by
any Governmental Authority or by any officer, department, agency or instrumentality thereof; fire; storm; flood; earthquake; accident;
war; rebellion; insurrection; riot; terrorism, and invasion, that interfere with the normal business operations of such party.

 

1.30
“General Assignment and Assumption Agreement” shall have the meaning provided in Section 2.6.1(ii).

 

1.31
“Governmental Authorities” shall mean all agencies, authorities, bodies, boards, commissions, courts, instrumentalities,
legislatures and offices of any nature whatsoever of any government or political subdivision, whether foreign, federal, state,
county, district, municipality, city or otherwise.

 

1.32
“Indemnifying Party” shall have the meaning provided in Section 8.4.

 

1.33
“Indemnitee” shall have the meaning provided in Section 8.4.

 

1.34
“Laws” shall mean any federal, state, foreign or local statute, law, ordinance, regulation, rule, code, Order,
other requirement or rule of law.

 

1.35
“Liability” shall mean any direct or indirect indebtedness, liability, assessment, expense, claim, loss, damage,
deficiency, obligation or responsibility, known or unknown, disputed or undisputed, joint or several, vested or unvested, executory
or not, fixed or unfixed, choate or inchoate, liquidated or unliquidated, secured or unsecured, determinable or undeterminable,
accrued or unaccrued, absolute or not, actual or potential, contingent or otherwise (including any liability under any guarantees,
letters of credit, performance credits or with respect to insurance loss accruals).

 

1.36
“[* * *]” shall have the meaning provided in Section 4.6.1.

 

1.37
“Lien” shall mean any mortgage, pledge, lien, conditional sale agreement, security title, encumbrance, easement,
right of way, charge or other title retention agreement of any kind or nature.

 

1.38
“Losses” shall have the meaning provided in Section 6.2.

 

1.39
“Non-Royalty Transaction Revenues” shall mean [* * *].

 

    	 	5	 

    	 

    

 

1.40
“Order” shall mean any order, judgment, preliminary or permanent injunction, temporary restraining order, award,
citation, decree, consent decree or writ of any Governmental Authority.

 

1.41
“Other Active” shall have the meaning given to such term in the [*
* *] Agreement.

 

1.42
“Person” shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization
or other entity, as well as any syndicate or group of any of the foregoing.

 

1.43
“Product” shall mean [* * *].

 

1.44
“Product Acguiror” shall mean the Third Party counterparty to a Product Transaction consummated by Eton after
the Restatement Date.

 

1.45
“Product Transaction” shall mean a transaction between Eton and a Third Party consummated after the Restatement
Date pursuant to which Eton conveys (whether by license, sale of assets, or a combination thereof) to such Third Party substantially
all of Eton’s rights to develop, manufacture and commercialize Products in the Territory; but, in each case, specifically
excluding any Excluded Transaction.

 

1.46
“Product Transaction Agreement” shall mean the definitive agreement(s) between Eton and the Product Acquiror
for the Product Transaction.

 

1.47
“Program” shall mean all activities related to Products, including all research, development, regulatory, manufacturing
and other related activities, conducted by or on behalf of Eyemax or its Affiliates.

 

1.48
“Purchased Assets” shall have the meaning provided in Section 2.1.

 

1.49
“Records” shall mean (a) all documentation comprising the Eyemax Registrations, including all submissions,
reports and correspondence relating thereto, (b) all tangible documentation comprising the Eyemax IP Rights and (b) any other
books and records relating exclusively to Product or the Program, or any other Purchased Assets, to the extent owned by or maintained
by or on behalf of Eyemax or any of its Affiliates.

 

1.50
“Recovery Amount” shall mean [* * *].

 

1.51
“Regulatory Approval Milestone Payment” shall have the meaning provided in Section 4.3.1.

 

    	 	6	 

    	 

    

 

1.52
“Regulatory Authority” shall mean any regulatory agency, ministry, department or other governmental body having
authority in any country or region to control the development, manufacture, marketing, and sale of pharmaceutical products, including
the FDA.

 

1.53
“Regulatory Approval” means, with respect to a Product in the Territory, any approval, registration, license,
or authorization from the FDA or any other Regulatory Authority in the Territory that is necessary to market and sell such Product
in the Territory.

 

1.54
“Regulatory Filing” shall mean any New Drug Application or Abbreviated New Drug Application, or any other application,
notification or submission made to or with the FDA for Regulatory Approval of a product, together with all amendments and supplements
to any of the foregoing.

 

1.55
“Restatement Date” shall have the meaning set forth in the recitals above.

 

1.56
“Royalties” shall mean all royalty payments actually received by Eton or any of its Affiliates from the Product
Acquiror with respect to Net Sales of Single Agent Products in the Territory by the Product Acquiror, its Affiliates, and the
Product Acquiror’s and its Affiliates’ respective licensees and sublicensees. For purposes of the preceding sentence,
“Net Sales” shall have the meaning set forth in the Product Transaction Agreement.

 

1.57
“Single Agent Product” shall have the meaning set forth in the [*
* *] Agreement.

 

1.58
“Tax Returns” means any and all reports, returns (including information returns), declarations, or statements
relating to Taxes, including any schedule or attachment thereto and any related or supporting workpapers or information with respect
to any of the foregoing, including any amendment thereof filed with or submitted to any Governmental Entity in connection with
the determination, assessment, collection or payment of Taxes or in connection with the administration, implementation or enforcement
of or compliance with any legal requirement relating to any Tax.

 

1.59
“Taxes” means any and all taxes, charges, fees, duties, contributions, levies or other similar assessments
or liabilities, including, without limitation, income, gross receipts, corporation, ad valorem, premium, value-added, net worth,
capital stock, capital gains, documentary, recapture, alternative or add-on minimum, disability, registration, recording, excise,
real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, employment, unemployment,
insurance, social security, national insurance, business license, business organization, environmental, workers compensation,
payroll, profits, severance, stamp, occupation, escheat, windfall profits, customs duties, franchise, estimated and other taxes
of any kind whatsoever imposed by the United States of America or any state, local or other government, or any agency or political
subdivision thereof, and any interest, fines, penalties, assessments or additions to tax imposed with respect to such items or
any contest or dispute thereof.

 

1.60
“Technology” shall mean, collectively, all forms and formulations comprising [* * *], all methods of manufacture
or use thereof, and all data, information, compositions, formulae, procedures, protocols, techniques and results of experimentation
and testing and other technology relating to or reasonably necessary or useful to make, use, sell, offer for sale, import, develop,
seek regulatory approval, market, commercialize or otherwise exploit the foregoing.

 

    	 	7	 

    	 

    

 

1.61
“Territory” shall mean collectively the United States of America and all of its territories and possessions.

 

1.62
“Third Party” shall mean any Person other than Eton, Eyemax or their respective Affiliates.

 

2.
Purchase and Sale of Purchased Assets.

 

2.1
Purchased Assets. Subject to the terms and conditions of this Restated Agreement, at the Closing, Eyemax shall sell, convey,
transfer, assign and deliver to Eton or its designee, and Eton shall purchase and acquire from Eyemax, all of Eyemax’s right,
title and interest as of the Closing in and to all of the following, free and clear of any and all Liens (collectively, the “Purchased
Assets”):

 

2.1.1
the Eyemax IP Rights and the Technology, in each case, in the Territory, and all rights to sue for or assert claims against and
remedies against past, present or future infringements of any or all of the Assigned Technology and rights of priority and protection
of interests therein and to retain any and all amounts therefrom (collectively, the “Assigned Technology”);

 

2.1.2
the Eyemax Registrations;

 

2.1.3
the [* * *] Agreement and all rights of Eyemax thereto as of the Closing Date;

 

2.1.4
the Records;

 

2.1.5
all claims, refund claims, causes of action, lawsuits or demands that Eyemax or any of its Affiliates may have against any Person,
whether arising by way of counterclaim or otherwise, and any judgments or recoveries in favor of or for the benefit of Eyemax
or any of its Affiliates; in each case, to the extent exclusively relating to the Program; and

 

2.1.6
all goodwill related to the Assigned Technology.

 

Eton
agrees that the Purchased Assets shall be delivered without any Eyemax warranties of whatever kind except for the representations
and warranties provided in Section 3.1 of this Restated Agreement. All assets of Eyemax and its Affiliates not specifically described
in Section 2.1 shall not be part of the sale and purchase contemplated hereunder and shall remain the property of Eyemax after
the Closing.

 

    	 	8	 

    	 

    

 

2.2
Assumed Liabilities. Except for the Assumed Liabilities, Eton shall not, by virtue of its purchase of the Purchased Assets,
assume or become responsible for any Liabilities of Eyemax or any other Person in connection with this Restated Agreement. As
previously agreed by the parties, as of the Closing, Eton shall assume and pay, perform, and discharge any and all Liabilities
of Eyemax under the [* * *] Agreement arising prior to, during, and relating to, the period on or after the Closing, including
any Liabilities imposed by applicable Law with respect to obligations under the [* * *] Agreement (the “[* * *] Liabilities”).
Further, Eton shall assume and pay, perform, and discharge any and all Liabilities of Eyemax under the Eyemax Registrations, solely
relating to the Territory arising prior to, during, and relating to, the period on or after the Closing (collectively, with the
[* * *] Liabilities and Liabilities of Eton under Section 5.1, the “Assumed Liabilities”); provided, however,
that the Assumed Liabilities shall exclude any and all Liabilities resulting from any breach of or non-compliance with the
[* * *] Agreement or Eyemax Registrations by Eyemax or any of its Affiliates on or prior to the later of the Closing Date or the
date of transfer of such Purchased Assets. All Liabilities of Eyemax or any of its Affiliates not specifically described in this
Section 2.2 (collectively, with the Liabilities of Eyemax under Section 5.1, the “Excluded Liabilities”) shall
not be assumed by Eton and shall remain the sole obligation and responsibility of Eyemax and its Affiliates after the Closing.

 

2.3
Purchase Price; Payment of Purchase Price. The aggregate consideration for the sale of the Purchased Assets shall be (i)
the assumption by Eton of the Assumed Liabilities and (ii) all payments that become due pursuant to Sections 4.3 and 4.4 (collectively,
the “Purchase Price”).

 

2.4
Closing. Unless this Restated Agreement has been terminated pursuant to its terms or unless another time or date is agreed
to in writing by the parties hereto, the closing of the sale and purchase of the Purchased Assets and the assumption of the Assumed
Liabilities (the “Closing”) shall take place on the same day as, and immediately prior to but contingent upon,
the Product Transaction at the offices of Cooley LLP, located at 4401 Eastgate Mall, San Diego, California 92121, unless another
place is agreed to in writing by the parties hereto or the parties hereto elect to effect the Closing by exchange of electronic
documents in PDF format in lieu of an in-person Closing. The date on which the Closing occurs is hereinafter referred to as the
“Closing Date.”

 

2.5
Transfer of Certain Purchased Assets. Eyemax shall transfer and deliver all Records (or true and complete copies thereof)
to Eton on the Closing Date to the extent possible or, to the extent not possible to transfer and deliver such items on the Closing
Date, within [* * *] days following the Closing Date, at Etan’s expense
for shipping and handling costs, to the locations, and in accordance with the instructions, specified by Eton or its designee.
In the event that any of the abovementioned items reside in digital or electronic format on any equipment that is not included
in the Purchased Assets, then the hard drive or other medium shall be imaged and provided to Eton or its designee in a reasonably
accessible format. Eyemax will, to the extent any Records exist in a form suitable for electronic transfer, make such transfer
electronically.

 

2.6
Closing Deliverables.

 

2.6.1
At the earlier of the Closing and the Product Transaction, Eyemax shall deliver or cause to be delivered to Eton (unless previously
delivered) the following:

 

(i)
a duly executed counterpart of a bill of sale in substantially the form of Exhibit A hereto with respect to the Purchased
Assets (other than the Eyemax IP Rights and the [* * *] Agreement), to be effective on the earlier of the Closing and the Product
Transaction (the “Bill of Sale”);

 

    	 	9	 

    	 

    

 

(ii)
a duly executed counterpart of an assignment and assumption agreement in substantially the form of Exhibit B hereto with
respect to the [* * *] Agreement and the Assumed Liabilities, to be effective on the earlier of the Closing and the Product Transaction
(the “General Assignment and Assumption Agreement”);

 

(iii)
[reserved];

 

(iv)
a true and complete copy of an assignment and consent agreement substantially in the form of Exhibit C hereto with respect
to the [* * *] Agreement duly executed by Eyemax and [* * *], to be effective on the earlier of the Closing and the Product Transaction
(the “[* * *] Consent”);

 

(v)
a true and complete copy of a duly executed letter (in form and substance satisfactory to Eton) to the FDA indicating that the
Eyemax Registrations are transferred to Eton or its designee and that Eton or its designee is the new owner of the Eyemax Registrations
as of the Closing Date;

 

(vi)
a certificate of a duly authorized officer of Eyemax, executed as of the Closing Date, certifying to the effect that the conditions
set forth in Section 6.1 shall have been satisfied; and

 

(vii)
such other good and sufficient instruments of conveyance, transfer and assignment as shall be necessary to vest in Eton or its
designee good and valid title to the other Purchased Assets, free and clear of all Liens, to be effective on the earlier of the
Closing and the Product Transaction.

 

2.6.2
At the earlier of the Closing and the Product Transaction, Eton shall deliver or cause to be delivered to Eyemax (unless previously
delivered) the following:

 

(i)
a counterpart of the Bill of Sale, duly executed by Eton;

 

(ii)
a counterpart of the General Assignment and Assumption Agreement, duly executed by Eton;

 

(iii)
[reserved]; and

 

(iv)
a certificate of a duly authorized officer of Eton, executed as of the Closing Date, certifying to the effect that the conditions
set forth in Section 6.2 shall have been satisfied.

 

2.7
License Grant. On the Closing Date, Eyemax hereby grants to Eton a non-exclusive, sublicensable, transferable, fully paid-up,
royalty-free, perpetual license to any_assets and rights owned, used or held for use by Eyemax, or to which Eyemax has rights,
that are related to, but not primarily related to, the Products or the Program in the Territory that are necessary or useful for
the development, manufacturing, commercialization or other exploitation of the Products in the Territory.

 

    	 	10	 

    	 

    

 

3.
Representations and Warranties.

 

3.1
Representations and Warranties of Eyemax. Eyemax hereby represents and warrants to Eton that, except as set forth on the
Disclosure Schedule attached hereto as Exhibit D (the “Disclosure Schedule”), which exceptions shall be deemed
to be part of the representations and warranties made hereunder, the representations under this Section 3.1 are true and complete
as of the Restatement Date and as of the Closing as follows:

 

3.1.1
Eyemax is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Massachusetts.
Eyemax is duly qualified to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature
of its activities and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions
in which failure to do so would not have a material adverse effect on Eyemax or its business.

 

3.1.2
Eyemax has the requisite power and authority and the legal right to execute and deliver this Restated Agreement, to perform its
obligations hereunder and thereunder, and to consummate the Acquisition. The execution, delivery and performance of this Restated
Agreement by Eyemax and the consummation by Eyemax of the Acquisition have been duly and validly authorized by all necessary action
of Eyemax, and no other action on the part of Eyemax is necessary to authorize this Restated Agreement or to consummate the Acquisition.
This Restated Agreement has been duly executed and delivered by Eyemax and, assuming the due authorization, execution and delivery
by Eton, this Restated Agreement constitutes a legal, valid and binding obligation of Eyemax, enforceable against Eyemax in accordance
with its terms, subject to the effect of any applicable bankruptcy, moratorium, insolvency, reorganization or other similar law
affecting the enforceability of creditors’ rights generally and to the effect of general principles of equity which may
limit the availability of remedies, whether in a proceeding at law or in equity (collectively, the “Bankruptcy Exception”).

 

3.1.3
All necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained
by Eyemax in connection with this Restated Agreement and the consummation of the Acquisition have been obtained, including, without
limitation, the written consent of [* * *] to the assignment to Eton of all of Eyemax’s rights and obligations under the
[* * *] Agreement. Neither the execution or delivery of this Restated Agreement by Eyemax does, nor the performance by Eyemax
of its obligations hereunder or thereunder or the consummation of the Acquisition will: (i) conflict with or violate any provision
of the organizational documents of Eyemax or any resolutions adopted by the Managers of Eyemax, (ii) conflict with, or constitute
a default under, any contractual obligation by which it is bound, or (iii) conflict with or violate any Law or Order applicable
to Eyemax or by which any of the Purchased Assets or Eyemax is bound or affected. Neither the execution or delivery of this Restated
Agreement, nor the performance by Eyemax of its obligations hereunder or thereunder or the consummation by Eyemax of the Acquisition
will: (a) result in the creation or imposition of any Lien on any of the Purchased Assets; or (b) violate or conflict with, or
result in a breach of, any provision of, or constitute a default under (or, with notice or lapse of time or both, would constitute
a default under) or give rise to any right of any Person other than Eyemax of termination, cancellation or modification, or acceleration
of any obligation of Eyemax or a loss of any rights or benefits to which Eyemax is entitled, in each case under any of the terms,
conditions or provisions of the [* * *] Agreement. There are no consents, approvals, permits, authorizations, waivers or other
actions by, or filings with or notifications to, any Governmental Authority that are required to be obtained or made by Eyemax
in connection with the execution, delivery and performance by Eyemax of this Restated Agreement or the performance of Eyemax’s
obligations hereunder and thereunder.

 

    	 	11	 

    	 

    

 

3.1.4
There is no claim, hearing, enforcement, audit, investigation, agency proceeding, charge, lawsuit, action or other legal proceeding
pending or, to the knowledge of Eyemax, currently threatened with respect to the Products, the Program, the Eton IP Rights, the
other Purchased Assets or the Assumed Liabilities, or that questions the validity of this Restated Agreement or the right of Eyemax
to enter into this Restated Agreement, or to consummate the transactions contemplated hereby. Eyemax is not subject to any Order
that would reasonably be expected to impair or delay its ability to perform its obligations under this Restated Agreement. There
is no order, writ, judgment, decision, ruling, subpoena, verdict, injunction, decree, consent decree, stipulation, determination
or award entered, issued, made or rendered by any Governmental Authority that is outstanding against Eyemax or any of its Affiliates
and that relates to or is reasonably likely to affect the Products, the Program or the Purchased Assets.

 

3.1.5
Neither Eyemax, its (sub)contractors, nor any of its or their officers, directors, employees or consultants, have been debarred
by the FDA or other applicable governing health authority (or authorities), under any existing or prior Law.

 

3.1.6
Eyemax has good, valid and marketable title to all Purchased Assets. The Purchased Assets include all data and information generated
by or on behalf of, or acquired by, Eyemax with respect to Products in the Territory. All of the Purchased Assets are owned by
Eyemax free and clear of all Liens, and upon the consummation of the Acquisition, Eton will acquire ownership of all of the Purchased
Assets, free and clear of all Liens.

 

3.1.7
No Eyemax Patents exist, and neither Eyemax nor any of its Affiliates owns or controls any potentially patentable invention directed
to any Product, including, without limitation, the formulation of, or any method of making or using, any Product, with respect
to which any patent application could be filed in the United States of America.

 

3.1.8
All material data, information, results of experimentation and testing provided by Eyemax to the FDA or Eton in relation to Products
or the Program are accurate and complete in all respects. No Eyemax Registrations made or other materials submitted by Eyemax
to the FDA or other Governmental Authority in the Territory contained an untrue statement of material fact when submitted, or
omitted to state a material fact within the knowledge of Eyemax when submitted which was required to be stated therein or necessary
in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

 

3.1.9
To the best of Eyemax’s knowledge after due inquiry but without performing a freedom to operate analysis, neither the Products
nor any use thereof infringes, misappropriates or otherwise violates the intellectual property rights of any Third Party. To the
knowledge of Eyemax, no Third Party is engaging in any activity that infringes, misappropriates or otherwise violates the Eyemax
IP Rights or the Eyemax Registrations.

 

3.1.10
Other than the 2017 Agreement and the [* * *] Agreement, neither Eyemax nor any of its Affiliates is a party to any license, sublicense
or other agreement pursuant to which any Third Party is granted.(i) any right to make, have made, use, sell, have sold, offer
for sale, import or otherwise distribute any Product or to otherwise exploit any Assigned Technology, (ii) any covenant not to
assert/sue or other immunity from suit under or any other rights to, any Assigned Technology, (iii) any ownership right or title,
whether actual or contingent, to any Assigned Technology, or (iv) an option or right of first refusal relating to any Assigned
Technology.

 

    	 	12	 

    	 

    

 

3.1.11
Other than the 2017 Agreement and the [* * *] Agreement, neither Eyemax nor any of its Affiliates is a party to any agreement
for development, manufacturing or other services with respect to any Product or that is primarily related to the Products, the
Program or the Purchased Assets. Eyemax has provided Eton with access to all material preclinical and clinical data in the possession
or control of Eyemax related to any Product. Eyemax has provided to Eton or made available current, true and complete copies of
all Eyemax Registrations.

 

3.1.12
Neither Eyemax nor any of its Affiliates has received any written notice from the FDA or any other Regulatory Authority alleging
any existing material non-compliance with any Laws applicable to the registration of any Product or the conduct of the Program.

 

3.1.13
No employee of Eyemax or any of its Affiliates has been excluded from participating in the Medicare program or any other program
of a Governmental Authority.

 

3.1.14
Neither Eyemax nor any of its Affiliates has received notice that the FDA or any other Regulatory Authority has taken, is taking
or intends to take action to limit, suspend, modify or revoke any of the Eyemax Registrations

 

3.1.15
With respect to the Products, the Program and the Purchased Assets, in each case solely with respect to the Territory, each of
Eyemax and its Affiliates and, to the knowledge of Eyemax, each of its and its Affiliates’ directors, officers and employees,
is and has been in compliance in all material respects with all applicable Laws in the Territory.

 

3.1.16
No agent, broker, investment banker or other Person is or will be entitled to any broker’s or finder’s fee or any
other commission or similar fee from Eyemax or its Affiliates in connection with the Acquisition or any of the other transactions
contemplated by this Restated Agreement.

 

3.1.17
The Purchased Assets constitute all assets and rights owned by Eyemax, or to which Eyemax has rights, that are primarily related
to the Products or the Program in the Territory.

 

3.1.18
Eyemax has delivered to or made available to Eton a true and complete copy of the [* * *] Agreement. The [* * *] Agreement is,
as to Eyemax (and, as to the other party thereto, to the knowledge of Eyemax), a legal, valid and binding agreement in full force
and effect and enforceable in accordance with its terms, subject to the effect of any Bankruptcy Exception. Eyemax is not in material
breach or default, and no event has occurred that with notice or lapse of time would constitute a material breach or default by
Eyemax under the [* * *] Agreement. To the knowledge of Eyemax, no other party to the [* * *] Agreement is in material breach
or default under, or has repudiated any material provision of, the [* * *] Agreement. Eyemax has not received any notice from
a counterparty to the [* * *] Agreement that such counterparty intends to terminate, cancel or amend (other than in a de minimis
respect) such [* * *] Agreement and there are no pending or unresolved notices from a counterparty to the [* * *] Agreement that
such counterparty intends to terminate, cancel or amend (other than in a de minimis respect) such [* * *] Agreement.

 

    	 	13	 

    	 

    

 

3.2
Representations and Warranties of Eton. Eton hereby represents and warrants to Eyemax as of the Restatement Date and as
of the Closing as follows:

 

3.2.1
Eton is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Eyemax is
duly qualified to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of its
activities and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions in
which failure to do so would not have a material adverse effect on Eton or its business.

 

3.2.2
Eton has the requisite power and authority and the legal right to execute and deliver this Restated Agreement, to perform its
obligations hereunder and thereunder, and to consummate the Acquisition. The execution, delivery and performance of this Restated
Agreement by Eton and the consummation by Eton of the Acquisition have been duly and validly authorized by all necessary action
of Eton, and no other action on the part of Eton is necessary to authorize this Restated Agreement or to consummate the Acquisition.
This Restated Agreement has been duly executed and delivered by Eton and, assuming the due authorization, execution and delivery
by Eton, this Restated Agreement constitutes a legal, valid and binding obligation of Eton, enforceable against Eton in accordance
with its terms, subject to the effect of any Bankruptcy Exception.

 

3.2.3
All necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained
by Eton in connection with this Restated Agreement and the consummation of the Acquisition have been obtained. Neither the execution
or delivery of this Restated Agreement by Eton does, nor the performance by Eton of its obligations hereunder or thereunder or
the consummation of the Acquisition will: (i) conflict with or violate any provision of the organizational documents of Eton or
any resolutions adopted by the board of directors of Eton, (ii) conflict with, or constitute a default under, any contractual
obligation by which it is bound, or (iii) conflict with or violate any Law or Order applicable to Eton.

 

3.2.4
There is no claim, hearing, enforcement, audit, investigation, agency proceeding, charge, lawsuit, action or other legal proceeding
pending or, to the knowledge of Eton, currently threatened against Eton that questions the validity of this Restated Agreement
or the right of Eton to enter into this Restated Agreement, or to consummate the transactions contemplated hereby.

 

3.2.5
Neither Eton, its (sub)contractors, nor any of its or their officers, directors, employees or consultants, have been debarred
by the FDA or other applicable governing health authority (or authorities), under any existing or prior law or regulation.

 

3.2.6
No agent, broker, investment banker or other Person is or will be entitled to any broker’s or finder’s fee or any
other commission or similar fee from Eton or its Affiliates in connection with the Acquisition or any of the other transactions
contemplated by this Restated Agreement.

 

4.
Financial Terms

 

4.1
Upfront Fee. Eyemax acknowledges timely receipt prior to the Restatement Date of payment in full of the upfront fee of
[* * *] under Section 6.1 of the 2017 Agreement.

 

4.2
Recovery Amount. The parties acknowledge that, as of the Restatement Date, Eton has not recovered the Recovery Amount and
agree that Eton shall be entitled to recover the entire Recovery Amount out of Non-Royalty Transaction Revenues and Royalties
received by Eton or its Affiliates in accordance with Sections 4.3.3 and 4.4.

 

    	 	14	 

    	 

    

 

4.3
Milestone Payments; Application of Non-Royalty Transaction Revenues and Royalties to Recovery Amount.

 

4.3.1
Within [* * *] days following the first achievement of all requisite Regulatory Approvals in the Territory by the FDA of the first
Single Agent Product, Eton shall pay to Eyemax a milestone payment of [* * *]
(the “Regulatory Approval Milestone Payment”).

 

4.3.2
Within [* * *] days following the First Commercial Sale of the first Single Agent Product in the Territory, Eton shall pay to
Eyemax a milestone payment of [* * *] (the “First Commercial Sale
Milestone Payment”).

 

4.3.3
After payment to Eyemax of the Regulatory Approval Milestone Payment and the First Commercial Sale Milestone Payment (or, if applicable,
the Required Payment, if the amount of the Required Payment is [* * *] as
provided in Section 4.3.4), Eton shall be entitled to retain 100% of the first [* * *]
of Non-Royalty Transaction Revenues and Royalties received by Eton or its Affiliates from the Product Acquiror, which
amounts shall be applied in full toward the Recovery Amount.

 

4.3.4
If the First Commercial Sale of the first Single Agent Product approved in the Territory has not occurred within one (1) year
of the Regulatory Approval date of such Single Agent Product (as such one (1) year period may be extended pursuant to Section
5.2 of the Product Acquisition Agreement) such that the First Commercial Sale Milestone Payment has not been paid or become payable
under Section 4.3.2, then, in the event that Eton receives a payment from the Product Acquiror pursuant to the last sentence of
Section 5.2 of the Product Transaction Agreement, then Eton shall, within [* * *] Days
of its receipt of such payment, remit to EyeMax, a payment in the amount of (i) [* *
*], if the amount of the payment to Eton from the Product Acquiror made pursuant to the last sentence of Section 5.2
of the Product Transaction Agreement is [* * *] or (ii) [*
* *], if the amount of the payment to Eton from the Product Acquiror made pursuant to the last sentence of Section
5.2 of the Product Transaction Agreement is [* * *] (the “Required
Payment”). For purposes of clarity, no Required Payment shall be payable in the event the First Commercial Sale Milestone
Payment becomes payable or has been paid hereunder.

 

4.4
Royalties and Non-Royalty Transaction Revenues Upon Satisfaction of Recovery Amount. After an aggregate of [*
* *] of Non-Royalty Transaction Revenues and Royalties has been applied to the Recovery Amount pursuant to Section
4.3.3 such that the remaining Recovery Amount is zero, Eton shall be entitled to retain 50%, and shall pay to Eyemax 50%, of all
Royalties and Non-Royalty Transaction Revenues, if any, actually received by Eton or its Affiliates from the Product Acquiror.
For the avoidance of doubt, nothing in this Section 4.4 shall excuse Eton from remitting the Required Payment to Eyemax if such
Required Payment is due to Eyemax pursuant to Section 4.3.4.

 

4.5
Royalty Reports and Payments. All payment amounts hereunder are expressed in, and all payments hereunder shall be payable
in, U.S. dollars. Within [* * *] following Eton’s or its Affiliates’
receipt from the Product Acquiror of any Non-Royalty Transaction Revenues and/or Royalties for a Calendar Quarter, Eton shall
deliver to Eyemax a report showing the amount of Non-Royalty Transaction Revenues and Royalties received by Eton or its Affiliates
from the Product Acquiror in such Calendar Quarter, and a copy of any report received by Eton or its Affiliates from the Product
Acquiror in such Calendar Quarter with respect to Net Sales of Single Agent Products in the Territory by the Product Acquiror,
its Affiliates, and the Product Acquiror’s and its Affiliates’ respective licensees and sublicensees, and the calculation
of Royalties with respect thereto. Eton shall remit any amounts due by Eton to Eyemax pursuant to Section4.4 with respect to Non-Royalty
Transaction Revenues and Royalties received by Eton or its Affiliates in such Calendar Quarter at the time such report is made.
Payment in whole or in part may be made in advance of such due date. No such Royalty reports or payments shall be due for any
Single Agent Product before the First Commercial Sale of such Single Agent Product. Eyemax agrees that, as a condition to receiving
such reports, if requested by the Product Acquiror, Eyemax shall enter into an appropriate and reasonable non-disclosure agreement
with the Product Acquiror regarding such reports and any other financial information of the Product Acquiror disclosable to Eyemax
under this Restated Agreement, including Section 4.7.

 

    	 	15	 

    	 

    

 

4.6
Interest: Withholding Taxes.

 

4.6.1
Any payment under Section 4.3 or Section 4.4 not paid when due shall bear interest from the due date until the date of payment
thereof at the rate of the [* * *] (“[* * *]”) as quoted
in [* * *] (or if it no longer exists, a similarly authoritative source);
provided, that interest shall not accrue at a rate that exceeds the maximum rate permitted by applicable law. The payment of such
interest shall not limit Eyemax from exercising any other rights it may have as a consequence of the lateness of any payment.

 

4.6.2
Eton shall be entitled to deduct the amount of any Taxes that are required to by paid with respect to such amounts payable by
Eton or its Affiliates, or any Taxes required to be withheld by Eton or its Affiliates from such amounts, to the extent Eton or
its Affiliates pay to the appropriate Governmental Authority on behalf of Eyemax such Taxes. Eton shall cooperate with Eyemax
in any lawful way reasonably requested by Eyemax to obtain available reductions, credits or refunds of such Taxes. Eton promptly
shall deliver to Eyemax proof of payment of all such Taxes, together with copies of all communications from or with any Governmental
Authority with respect thereto.

 

4.7
Audits.

 

4.7.1
Upon the written request of Eyemax and not more than once in each calendar year, Eton shall permit an independent certified public
accounting firm of nationally recognized standing selected by Eyemax and reasonably acceptable to Eton, at Eyemax’ s expense,
to have access during normal business hours to such of the financial records of Eton as may be reasonably necessary to verify
the accuracy of the reports hereunder for the eight (8) Calendar Quarters immediately prior to the date of such request (other
than records for which Eyemax has already conducted an audit under this Section).

 

4.7.2
If such accounting firm concludes that additional amounts were owed during the audited period, Eton shall pay such additional
amounts within [* * *] after the date Eyemax delivers to Eton such accounting
firm’s written report so concluding. The fees charged by such accounting firm shall be paid by Eyemax; provided, however,
that to the extent the auditor determines an underpayment discrepancy greater than five percent (5%), Eton shall pay the reasonable
fees and expenses charged by such accounting firm.

 

4.7.3
Eyemax shall cause its accounting firm to retain all financial information subject to review under this Section 4.7 in strict
confidence; provided, however, that Eton shall have the right to require that such accounting firm, prior to conducting
such audit, enter into an appropriate and reasonable non-disclosure agreement with Eton regarding such financial information.
The accounting firm shall disclose to Eyemax only whether the reports are correct or not and the amount of any discrepancy. No
other information shall be shared. Eyemax shall treat all such financial information as Eton’s confidential information,
and shall not disclose such financial information to any Third Party or use it for any purpose other than as specified in this
Section 4.7.

 

    	 	16	 

    	 

    

 

5.
Covenants.

 

5.1
Tax Matters.

 

5.1.1
Eyemax shall be responsible for and shall pay all Taxes of Eyemax for all periods and all Taxes that relate to the Purchased Assets
that were incurred in or are attributable to any taxable period (or portion thereof) ending on or before the Closing Date. Eyemax
shall prepare and file its Tax Returns for all periods and all Tax Returns that relate to the Purchased Assets for any Taxable
periods ending on or before the Closing Date. Such returns will be prepared and filed in accordance with applicable Law and in
a manner consistent with past practices.

 

5.1.2
Any real property, personal property or similar Taxes applicable to the Purchased Assets for a taxable period that includes but
does not end on the Closing Date shall be paid by Eton or Eyemax, as applicable, and such Taxes shall be apportioned between Eton
and Eyemax based on the number of days in the portion of the taxable period that ends on the Closing Date (the “Pre-Closing
Tax Period”) and the number of days in the entire taxable period. Eyemax shall pay Eton an amount equal to any such
Taxes payable by Eton which are attributable to the Pre-Closing Tax Period, and Eton shall pay Eyemax an amount equal to any such
Taxes payable by Eyemax which are not attributable to the Pre-Closing Tax Period. Such payments shall be made on or prior to the
Closing Date or, if later, on the date such Taxes are due (or thereafter, promptly after request by Eton or Eyemax if such Taxes
are not identified by Eton or Eyemax on or prior to the Closing Date).

 

5.1.3
All transfer, value added taxes, withholding, sales, and use taxes, deed excise stamps and similar charges (“Transfer
Taxes”) related to the sale of the Purchased Assets contemplated by this Restated Agreement shall be paid by Eyemax.
The party required under applicable Law will file any necessary Tax Returns and other documentation with respect to all such Taxes
and, if Eton is required by applicable Law to file such Tax Returns, Eyemax shall pay over to Eton any such Transfer Taxes payable
with respect to such Tax Return.

 

5.1.4
After the Closing, upon reasonable written notice, Eton and Eyemax shall furnish or cause to be furnished to each other, as promptly
as practicable, such information and assistance (to the extent within the control of such party) relating to the Purchased Assets
and Assumed Liabilities (including, access to books and records) as is reasonably necessary for the filing of all Tax Returns,
the making of any election related to Taxes, the preparation of any available Tax clearance certificate, the preparation for any
audit by any Governmental Entity, and the prosecution or defense of any claim, suit or proceeding related to any Tax Return. Eyemax
and Eton shall cooperate with each other in the conduct of any audit or other proceeding relating to Taxes involving the Purchased
Assets and Assumed Liabilities. Eyemax shall not after the Closing take any position in any Tax Return, or reach any settlement
or agreement on audit, which is in any manner inconsistent with any position taken by Eyemax in any filing, settlement or agreement
made by Eyemax prior to the Closing if such inconsistent position (i) requires the payment by Eton of more Tax than would have
been required to be paid had such position not been taken or such settlement or agreement not been reached, (ii) affects the determination
of useful life, basis or method of depreciation, amortization or accounting of any of the Purchased Assets or any of the properties,
assets or rights of Eton or (iii) accelerates the time at which any Tax must be paid by Eton; unless Eton has previously consented
to such position in a writing to Eyemax.

 

    	 	17	 

    	 

    

 

5.2
Confidentiality.

 

5.2.1
Except as otherwise provided herein, Eyemax shall treat as confidential and shall safeguard any and all nonpublic, confidential
or proprietary information included in the Purchased Assets (“Confidential Information”), in each case by using
the same degree of care, but no less than a reasonable standard of care, to prevent the unauthorized use, dissemination or disclosure
of such Confidential Information.

 

5.2.2
Eton and Eyemax acknowledge that the confidentiality obligations set forth herein shall not extend to any information which was
in, or comes into, the public domain through no breach of this Restated Agreement or the 2017 Agreement by Eyemax. In addition,
Eyemax shall not be prohibited from disclosing any portion of the Confidential Information that Eyemax is required to disclose
by judicial or administrative process or, in the opinion of legal counsel, by other requirements of Law.

 

5.2.3
In the event of a breach of the obligations hereunder by Eyemax, Eton, in addition to all other available remedies, will be entitled
to seek injunctive relief to enforce the provisions of this Section 5.2 in any court of competent jurisdiction.

 

5.3
Assistance in Proceedings. Eyemax will cooperate with Eton and its counsel in the contest or defense of, and make available
its personnel and provide any testimony and access to its books and records in connection with, any proceeding involving or relating
to (a) any transaction contemplated by this Restated Agreement or (b) any action, activity, circumstance, condition, conduct,
event, fact, failure to act, incident, occurrence, plan, practice, situation, status or transaction on or before the Closing Date
involving Eyemax or the Purchased Assets.

 

5.4
Transfer of Eyemax Registrations: Interim Responsibility.

 

5.4.1
On the Closing Date, Eyemax shall assign to Eton or its designee any and all Eyemax Registrations in accordance with this Section
5.4, except only for only any regulatory filings Eton requests in writing not to be assigned. On the Closing Date, Eyemax will
forward to Eton complete copies of the Eyemax Registrations and copies of all correspondence with, and periodic and other reports
(including adverse event reports and the underlying data) to, Regulatory Authorities with respect to the Products or Eyemax Registrations.

 

5.4.2
On the Closing Date, Eyemax shall (i) send letters (in form and substance satisfactory to Eton) to the FDA and other Regulatory
Authorities indicating that the Eyemax Registrations are transferred to Eton or its designee and that Eton or its designee is
the new owner of the Eyemax Registrations as of the Closing Date, and (ii) provide to Eton a copy of said letters.

 

5.4.3
The parties will cooperate to ensure a smooth transition from Eyemax to Eton or its designee of all of the activities required
to be undertaken by the Eyemax Registrations holder. Eyemax will cooperate with Eton or its designee to ensure a smooth transition
of the Program and the transfer of adverse experience reporting obligations from Eyemax to Eton or its designee. At the reasonable
request of Eton, Eyemax shall use commercially reasonable efforts to assist Eton, at Eton’s cost, with matters relating
to the approval of the Eyemax Registrations by the FDA, including reviewing and providing comments on correspondence to and from
the FDA with respect to such Eyemax Registrations and otherwise advising Eton on matters relating to such Eyemax Registrations
and their approval.

 

    	 	18	 

    	 

    

 

5.4.4
Until the Eyemax Registrations have been transferred to Eton or its designee, Eyemax shall be responsible for maintaining them.
After such transfer, Eton or its designee will assume all responsibility for the Eyemax Registrations, at its sole cost and expense.
Each party shall cooperate with the other in making and maintaining all regulatory filings that may be necessary in connection
with the execution, delivery and performance of this Restated Agreement.

 

5.4.5
On the Closing Date, Eyemax will transfer to Eton or its designee, at no cost to either of them, any and all documented Eyemax
Know-How and Technology in its possession and control, and Eyemax will, to the extent any such Eyemax Know-How or Technology exists
in a form suitable for electronic transfer, make any transfer electronically.

 

5.5
Communication With Agencies. Until the Eyemax Registrations are transferred to Eton or its designee, Eyemax shall have
responsibility for all communications with the FDA relating to the Products, and Eyemax will promptly provide Eton or its designee
with copies of all communications to or from the FDA with respect to the Products and/or the manufacture thereof. After such transfer
has been completed, as between the parties, Eton shall have responsibility for all such communications. Eyemax shall promptly
provide Eton with copies of any communications or contacts it sends to or receives from any other Governmental Authority concerning
the Products.

 

5.6
Further Assurances. From time to time after the Closing Date, each party hereto shall, and shall cause its Affiliates,
promptly to execute, acknowledge and deliver any other assurances or documents or instruments of transfer reasonably requested
by the other party hereto and necessary for the requesting party to satisfy its obligations hereunder or to obtain the benefits
of the Acquisition. Without limiting the generality of the foregoing, to the extent that Eton or Eyemax discover following Closing
that any asset that was intended to be transferred pursuant to this Restated Agreement was not transferred at Closing, Eyemax
shall or shall cause its Affiliates promptly to assign and transfer to Eton or its designee all right, title and interest in such
asset, Eyemax shall or shall cause its Affiliates to assist Eton or its designee with respect to the prosecution, maintenance
and enforcement of the Assigned Technology by Eton or its designee after the Closing, including submitting on behalf of Eton or
its designee any oaths, declarations or affidavits as required or advisable under applicable Law.

 

5.7
In the event that Eton’s recovery of any milestone payment or royalty payment due to Eton under Section 5.2 or Section 5.3
of the Product Transaction Agreement from the Product Acquiror occurs as the result of litigation pursuant to Section 10.2:2 of
the Product Transaction Agreement, then Eton shall have the right to set off 50% of its litigation costs and expenses, including
attorneys’ fees, incurred in connection with such litigation, against any amounts payable to Eyemax pursuant to Sections
4.3.2, 4.3.4 or 4.4.

 

5.8
During the seven (7) years following the Closing, Eyemax shall not, and shall cause its Affiliates not to, directly or indirectly,
manufacture, use, develop, promote, market, sell, offer to sell, distribute or license in the Territory any product that contains
[* * *], whether as the sole active ingredient or with Other Actives (collectively, the “Competing Business”);
provided, however, the restriction contained in this Section 5.8 shall not prohibit Eyemax or its Affiliates from
owning less than five percent (5%) of the outstanding stock of any class of securities registered under the Securities Exchange
Act of 1934, as amended; provided, further, that if, during such seven (7)-year period, any Competing Business is
conducted in the Territory at the time of consummation of an Acquisition Transaction (as defined below) by any business (or any
portion thereof), Person or group of Persons, all or a majority interest of which is, or a bundle of assets of which are, acquired
by Eton or any of its Affiliates through an equity or asset purchase, merger, consolidation or other transaction, in each case,
whether in a single transaction or a series of related transactions (an “Acquisition Transaction”), then Eyemax
or its Affiliates may continue to conduct such Competing Business until the earlier of (i) such time as Eyemax or its Affiliates
divest such Competing Business and (ii) four (4) months after the closing date of such Acquisition Transaction; provided,
however, that no Acquisition Transaction can be entered into by Eyemax or any of its Affiliates if the Competing Business
is all or substantially all of the business that would be purchased pursuant to the Acquisition Transaction. For the avoidance
of doubt, nothing in this Section 5.8 shall prohibit Eyemax or its Affiliates from being acquired by any Person or group of Persons
(including a Person or group of Persons engaged in a Competing Business prior to the date of such acquisition of Eton) and the
restrictions of this Section 5.8 shall not apply with respect to any Competing Business conducted by any such acquirer or its
Affiliates (other than Eyemax or Eyemax’s subsidiaries) prior to the acquisition of Eyemax, if any. Eyemax acknowledges
that the agreements in this Section 5.8 impose a reasonable restraint in light of the activities and business of Eyemax and its
Affiliates on the Effective Date and the current business of Eton, Eyemax and their respective Affiliates.

 

    	 	19	 

    	 

    

 

6.
Conditions to Closing.

 

6.1
Conditions to Obligations of Eton. The obligation of Eton to effect the Closing is subject to the satisfaction (or waiver)
prior to the Closing of the following conditions:

 

6.1.1
The representations and warranties of Eyemax, as specified in Section 3.1 shall be true and correct on and as of the Restatement
Date and as of the Closing, as though made on and as of the Closing (except to the extent expressly made as of an earlier date,
in which case as of the earlier date).

 

6.1.2
Eyemax shall have performed and complied with all of its covenants contained in Section 5 (disregarding any failure to perform
or comply that was inadvertent or unintentional) at or before the Closing (to the extent that such covenants require performance
by Eyemax at or before the Closing).

 

6.1.3
Eton shall have received a certificate, signed by a duly authorized officer of Eyemax and dated the Closing Date, to the effect
that the conditions set forth in Sections 6.1.1 and 6.1.2 have been satisfied.

 

6.1.4
The Product Transaction shall have occurred.

 

6.1.5
The [* * *] Consent shall have been obtained and shall be in full force and effect.

 

6.1.6
Eyemax shall have furnished to Eton all deliverables set forth in Section 2.6.1.

 

6.1.7
No temporary restraining Order, preliminary or permanent injunction or other Order preventing the consummation of the Acquisition
oi the Product Transaction shall have been issued by any court of competent jurisdiction and remain in effect.

 

    	 	20	 

    	 

    

 

6.2
Conditions to Obligations of Eyemax. The obligation of Eyemax to effect the Closing is subject to the satisfaction (or
waiver) prior to the Closing of the following conditions.

 

6.2.1
The representations and warranties of Eton, as specified in Section 3.2 shall be true and correct on and as of the Restatement
Date and as of the Closing, as though made on and as of the Closing (except to the extent expressly made as of an earlier date,
in which case as of the earlier date).

 

6.2.2
Eton shall have performed and complied with all of its covenants contained in Section 5 (disregarding any failure to perform or
comply that was inadvertent or unintentional) at or before the Closing (to the extent that such covenants require performance
by Eton at or before the Closing).

 

6.2.3
Eyemax shall have received a certificate, signed by a duly authorized officer of Eton and dated the Closing Date, to the effect
that the conditions set forth in Sections 6.2.1 and 6.2.2 have been satisfied.

 

6.2.4
The Product Transaction shall have occurred.

 

6.2.5
Eton shall have furnished to Eyemax all deliverables set forth in Section 2.6.2.

 

6.2.6
No temporary restraining Order, preliminary or permanent injunction or other Order preventing the consummation of the Acquisition
oi the Product Transaction shall have been issued by any court of competent jurisdiction and remain in effect.

 

7.
Termination.

 

7.1
Termination. This Restated Agreement may be terminated prior to the Closing:

 

7.1.1
by the mutual written consent of the parties; or

 

    	 	21	 

    	 

    

 

7.1.2
by Eton by written notice to Eyemax if Eton is not then in material breach of any provision of this Restated Agreement and there
has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Eyemax pursuant
to this Restated Agreement that would give rise to the failure of any of the conditions specified in Section 6.1.1 or Section
6.1.2 and such breach, inaccuracy or failure has not been cured by Eyemax within [* *
*] of Eyemax’s receipt of written notice of such breach from Eton; or

 

7.1.3
by Eyemax by written notice to Eton if Eyemax is not then in material breach of any provision of this Restated Agreement and there
has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Eton pursuant
to this Restated Agreement that would give rise to the failure of any of the conditions specified in Section 6.2.1 or Section
6.2.2 and such breach, inaccuracy or failure has not been cured by Eton within [* * *]
days of Eton’s receipt of written notice of such breach from Eyemax; or

 

7.1.4
by either party upon written notice to the other party at any time after March 31, 2019 (the “End Date”) if
the Closing has not taken place on or before the End Date, unless the failure of the Closing to take place on or before such date
is attributable to a breach by such party of any of its obligations set forth in this Restated Agreement; or

 

7.1.5
by Eton or Eyemax in the event that a court of competent jurisdiction shall have issued a final and nonappealable Order having
the effect of permanently restraining, enjoining or otherwise prohibiting the Transaction; provided, however, that a party
shall not be permitted to terminate this Restated Agreement pursuant to this Section 7.1.5 if such party did not use commercially
reasonable best efforts to have such Order vacated prior to its becoming final and nonappealable.

 

7.2
Effect of Termination. In the event of the termination of this Restated Agreement in accordance with Section 7.1, this
Restated Agreement shall become void and have no effect, and neither party hereto shall have any liability to the other party
hereto or their respective Affiliates, or their respective directors, officers or employees, except for the obligations of the
parties hereto contained in this Section 7.2 and in Section 9 (and any related definitional provisions set forth in Article 1),
and except that nothing in this Section 7.2 shall relieve either party from (i) making any payments due to the other party prior
to the termination notice date pursuant to the terms of the 2017 Agreement oi (ii) liability for any willful and material breach
of this Restated Agreement that arose prior to such termination, for which liability the provisions of Section 8 shall remain
in effect in accordance with the provisions and limitations of such Section.

 

    	 	22	 

    	 

    

 

8.
Indemnification.

 

8.1
Survival.

 

8.1.1
Except in the case of Eyemax’s common law fraud, Eyemax’s obligations to indemnify and hold harmless an Eton Indemnitee
pursuant to Section 8.2(i): (x) other than with respect to the representations and warranties set forth in Sections 3.1.1, 3.1.2,
3.1.3 (clause (i) of the second sentence), 3.1.6 (first and third sentences), 3.116 and 3.1.17 (the “Eyemax Fundamental
Representations”), shall terminate on the date that is twenty-four (24) months from the date of this Restated Agreement,
and (y) with respect to the Eyemax Fundamental Representations shall survive indefinitely; provided, however, that such obligations
to indemnify and hold harmless shall not terminate with respect to any item as to which an Eton Indemnitee shall have, before
the expiration of such applicable period, previously made a claim by delivering a notice of such claim in accordance with this
Restated Agreement to Eyemax, which obligations shall survive until all such claims have been resolved.

 

8.1.2
Except with respect to Eton’s common law fraud, Eton’s obligations to indemnify and hold harmless an Eyemax Indemnitee
pursuant to Section 8 3(i): (x) other than with respect to the representations and warranties set forth in Sections 3.2.1, 3.2.2,
3.2.3 (clause (i) of the second sentence) and 3.2.6 (the “Eton Fundamental Representations”), shall terminate
on the date that is twenty-four (24) months from the date of this Restated Agreement and (y) with respect to the Eton Fundamental
Representations shall survive indefinitely; provided, however, that such obligations to indemnify and hold harmless shall not
terminate with respect to any item as to which an Eyemax Indemnitee shall have, before the expiration of such applicable period,
previously made a claim by delivering a notice of such claim in accordance with this Restated Agreement to Eton, which obligations
shall survive until all such claims have been resolved.

 

8.1.3
All of the covenants and agreements contained in this Restated Agreement that by their nature are required to be performed after
the Closing shall survive the Closing until fully performed or fulfilled.

 

8.2
Indemnification by Eyemax. Eyemax shall indemnify, defend and hold harmless Eton, its Affiliates, the Product Acquiror,
and its and their respective officers, directors, shareholders, employees, agents and representatives (collectively “Eton
Indemnitees”) from any and all losses, liabilities, damages and expenses, including reasonable attorneys’ fees
and costs (collectively, “Losses”) arising from, in connection with or otherwise with respect to (i) any inaccuracy
in, or breach of, any representation or warranty of Eyemax contained in Section 3.1 of this Restated Agreement or in any Ancillary
Agreement, (ii) any failure by Eyemax to perform, fulfill or comply with any covenant, agreement, obligation or undertaking of
Eyemax contained in this Restated Agreement or in any Ancillary Agreement and (iii) the Excluded Liabilities.

 

8.3
Indemnification by Eton. Eton shall indemnify, defend and hold harmless Eyemax, its Affiliates, and its and their respective
officers, directors, shareholders, employees, agents and representatives (collectively “Eyemax Indemnitees”)
from any and all Losses arising from, in connection with or otherwise with respect to (i) any inaccuracy in, or breach of, any
representation or warranty of Eton contained in Section 3.2 of this Restated Agreement or in any Ancillary Agreement, (ii) any
failure by Eton to perform, fulfill or comply with any covenant, agreement, obligation or undertaking of Eton contained in this
Restated Agreement or in any Ancillary Agreement and (iii) the Assumed Liabilities.

 

    	 	23	 

    	 

    

 

8.4
Third Party Claim Procedures. A party seeking indemnification (the “Indemnitee”) shall promptly notify
the other party (the “Indemnifying Party”) in writing of a claim, demand, action or proceeding; provided that
an Indemnitee’s failure to give such notice or delay in giving such notice shall not affect such Indemnitee’s right
to indemnification under this Section 8 except to the extent that the Indemnifying Party has been prejudiced by such failure or
delay. The Indemnifying Party shall have the right to control the defense of all indemnification claims hereunder. The Indemnitee
shall have the right to participate at its own expense in the claim, action or proceeding with counsel of its own choosing. The
Indemnifying Party shall consult with the Indemnitee in good faith with respect to all non-privileged aspects of the defense strategy.
The Indemnitee shall cooperate with the Indemnifying Party as reasonably requested, at the Indemnitee’s sole cost and expense.
The Indemnifying Party shall not settle any claim, demand, action or proceeding with respect to which without the Indemnitee’s
prior written consent, which consent shall not be unreasonably withheld.

 

8.5
Direct Claim Procedures. In the event any Indemnitee should have a claim against an Indemnifying Party under Section 8.2
or Section 8.3, as applicable, that does not involve a Third Party claim being asserted against or sought to be collected from
such Indemnitee, the Indemnitee shall deliver notice of such claim to the Indemnifying Party. The failure by any Indemnitee so
to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability that it may have to such Indemnitee
under Section 8.2 or Section 8.3, as applicable, except to the extent (and only to the extent) that the Indemnifying Party shall
have been actually and materially prejudiced as a result of such failure. If the Indemnifying Party does not notify the Indemnitee
within [* * *] following its receipt of such notice that the Indemnifying
Party disputes Indemnifying Party’s liability to the Indemnitee under Section 8.2 or Section 8.3, as applicable, such claim
specified by the Indemnitee in such notice shall be conclusively deemed a Loss of the Indemnifying Party under Section 8.2 or
Section 8.3, as applicable, and Indemnifying Party shall pay the amount of such Loss to the Indemnitee on demand or, in the case
of any notice in which the amount of the claim (or any portion thereof) is estimated, on such later date when the amount of such
claim (or such portion thereof) becomes finally determined.

 

8.6
Exclusive Monetary Remedy; Limitations.

 

8.6.1
Except in the case of common law fraud, the right to indemnification under this Section 8 shall constitute the sole and exclusive
monetary remedy of the Eton Indemnitees and the Eyemax Indemnitees for Losses or otherwise arising from, in connection with this
Purchase Agreement, including pursuant to Section 8.1.1, Section 8.1.2, Section 8.1.3, Section 8.2, Section 8.3, the Ancillary
Agreements or otherwise with respect to any of the transactions contemplated hereby or thereby.

 

8.6.2
Except in the case of Eyemax’s common law fraud, (x) except for a breach of the Eyemax Fundamental Representations, Eyemax’s
aggregate liability to Eton Indemnitees pursuant to Section 8.2(i) shall not exceed [*
* *] plus [* * *] of each Non-Royalty Transaction Revenue payment,
milestone payment or Royalty payment that is earned by Eyemax under Section 4.3 and Section 4.4 of this Restated Agreement (the
“Cap”), and (y) other than (A) with respect to Section 8.2(iii) (with respect to which Eyemax’s liability
shall not be limited), (B) Section 8.2(ii) with respect to Sections 2.1, 2.5, 2.6.1, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.8 and 9 (with
respect to which Eyemax’s liability shall not be limited) and (C) Eyemax Fundamental Representations (with respect to which
Eyemax’s liability shall not be limited), Eyemax’s aggregate liability under Section 8.2 shall not exceed the greater
of (i) the sum of the Non-Royalty Transaction Revenues, milestones and Royalties actually paid by Eton to Eyemax under this Restated
Agreement and (ii) $[* * *]. No Eton Indemnitee shall be entitled to recover
any Losses under Section 8.2(i) unless and until the aggregate Losses for which they would otherwise be entitled to indemnification
under Section 8.2(i) exceed $[* * *], at which point the Eyemax Indemnitees
shall become entitled to be indemnified for such Losses in excess of $[* * *].

 

    	 	24	 

    	 

    

 

8.6.3
Except in the case of Eton’s common law fraud, (x) except for a breach of the Eton Fundamental Representations, Eton’s
aggregate liability to Eyemax Indemnitees pursuant to Section 8.3(i) shall not exceed the Cap, and (y) other than (A) with respect
to Section 8.3(iii) (with respect to which Eton’s liability shall not be limited) and (B) Section 8.3(ii) with respect to
Sections 4.3, 4.4, 4.5 and 9 (with respect to which Eton’s liability shall not be limited), Eton’s aggregate liability
under Section 8.3 shall not exceed the greater of (i) the sum of the Non-Royalty Transaction Revenues, milestones and Royalties
actually paid by Eton to Eyemax under this Restated Agreement and (ii) $[* * *].
No Eyemax Indemnitee shall be entitled to recover any Losses under Section 8.3(i) unless and until the aggregate Losses for which
they would otherwise be entitled to indemnification under Section 8.3(i) exceed $[* *
*], at which point the Eton Indemnitees shall become entitled to be indemnified for such Losses in excess of $[*
* *].

 

8.7
Tax Treatment of Indemnification Payments. All indemnity payments made by an Indemnifying Party to an Indemnitee pursuant
to this Restated Agreement shall be treated for all Tax purposes as adjustments to the Purchase Price.

 

8.8
Right of Set-Off. Notwithstanding any provision of this Restated Agreement to the contrary, the parties acknowledge and
agree that, in addition to any other right hereunder, subject to the limitations set forth in Section 8.6, Eton shall have the
right, but not the obligation, from time to time to set off any Losses for which the Eton Indemnitees are entitled to indemnification
hereunder against any payment pursuant to Section 4.3 or Section 4.4.

 

8.9
Specific Performance. In the event of any breach or threatened breach by either party of any covenant, obligation or other
provision set forth in this Restated Agreement, the other party shall be entitled (in addition to any other remedy that may be
available to it) to (i) a decree or order of specific performance or mandamus to enforce the observance and performance of such
covenant, obligation or other provision, and (ii) an injunction restraining such breach or threatened breach; and (b) such party
shall not be required to provide any bond or other security in connection with any such decree, order or injunction or in connection
with any related action or proceeding.

 

8.10
No Implied Representations. The parties acknowledge and agree that, except as expressly provided in Section 3.1 and Section
3.2, neither of the parties hereto has made or is making any representations or warranties whatsoever, implied or otherwise.

 

8.11
LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, EXCEPT FOP THE OBLIGATIONS TO INDEMNIFY, DEFEND
AND HOLD HARMLESS PURSUANT TO THIS SECTION 8 FOR THIRD PARTY CLAIMS OR IN THE CASE OF BREACH OF THE CONFIDENTIALITY OBLIGATIONS
PURSUANT TO SECTION 5.2, NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE
DAMAGES, WHETHER FORESEEABLE OR NOT, ARISING OUT OF THIS RESTATED AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, REGARDLESS
OF ANY NOTICE OF SUCH DAMAGES.

 

    	 	25	 

    	 

    

 

8.12
Litigation Support. Following the Closing, the parties shall reasonably cooperate with each other in the defense or settlement
of any claims or lawsuits brought by, Third Parties that involve the Purchased Assets, the Product, this Restated Agreement or
the transactions contemplated hereby by providing the other party and such other party’s legal counsel reasonable access
to employees, records, documents, data, equipment, facilities, products, and other information relating primarily to the Products,
the Program and the Purchased Assets as such other party may reasonably request, to the extent maintained or under the possession
or control of the requested party; provided, however, that such access shall not unreasonably interfere with the
parties’ respective businesses; and provided, further, that either party may restrict the foregoing access to the extent
that (a) such restriction is required by applicable Law, (b) such access or provision of information would result in a violation
of confidentiality obligations to a Third Party or (c) disclosure of any such information would result in the loss or waiver of
the attorney-client privilege.

 

9.
Miscellaneous.

 

9.1
Relationship of Parties. The relationship between Eyemax and Eton, with respect to this Restated Agreement, is only that
of independent contractors notwithstanding any activities set forth in this Restated Agreement. Neither party is the agent or
legal representative of the other party, and neither party has the right or authority to bind the other party in any way. This
Restated Agreement creates no relationship as partners or a joint venture, and creates no pooling arrangement.

 

9.2
Governing Law and Resolution of Disputes.

 

9.2.1
This Restated Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference
to its conflict of laws principles.

 

9.2.2
Any and all disputes or claims arising from or out of this Restated Agreement shall be litigated exclusively before a court of
the State of Delaware or, if subject matter jurisdiction exists, the United States District Court for the District of Delaware.
Each party hereto hereby irrevocably and unconditionally consents to the exclusive personal jurisdiction and service of, and venue
of, any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim that any action, lawsuit
or proceeding brought in any such court has been brought m an inconvenient forum. Any judgment issued by such a court may be enforced
in any court having jurisdiction.

 

    	 	26	 

    	 

    

 

9.3
Assignment. Neither party shall assign its rights or obligations under this Restated Agreement without the prior written
consent of the other party, which shall not be unreasonably withheld or delayed; provided, however, that a party may, without
such consent, assign this Restated Agreement and its rights and obligations hereunder (a) to any Affiliate, or (b) in connection
with the transfer or sale of all or substantially all of its business to which this Restated Agreement relates, or in the event
of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of
its assignor under this Restated Agreement Any purported assignment in violation of this Section 9.3 shall be void.

 

9.4
Counterparts. This Restated Agreement may be executed in several counterparts that together shall be originals and constitute
one and the same instrument.

 

9.5
Waiver. The failure of any party to enforce any of its rights hereunder or at law shall not be deemed a waiver of any of
its rights or remedies against another party, unless such waiver is in writing and signed by the party to be charged. No such
waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature or any other breach or default
by such other party. All rights and remedies conferred herein shall be cumulative and in addition to all of the rights and remedies
available to each party at law, equity or otherwise.

 

9.6
Severability. If any provision of this Restated Agreement, or part thereof, is declared by a court of competent jurisdiction
to be invalid, void or unenforceable, each and every other provision, or part thereof, shall nevertheless continue in full force
and effect.

 

9.7
Notices. Any consent, notice or report required or permitted to be given or made under this Restated Agreement by a party
to the other party shall be in writing, delivered by any lawful means to such other party at its address indicated below, or to
such other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in
this Restated Agreement) shall be effective upon receipt by the addressee.

 

	 	If
    to Eyemax:	Eyemax
    LLC
	 	 	74
    Chestnut Street
	 	 	Weston,
    Massachusetts 02493
	 	 	Attention:
    Di Elias Reichel
	 	 	 
	 	If
    to Eton:	Eton
    Pharmaceuticals, Inc
	 	 	21925
    Field Pkwy, Suite 235
	 	 	Deer
    Park, Illinois 60010
	 	 	Attention:
    Chief Executive Officer

 

9.8
Further Assurances. The parties agree to execute such additional documents and perform such acts as are reasonably necessary
to effectuate the intent of this Restated Agreement.

 

    	 	27	 

    	 

    

 

9.9
Entire Agreement. Effective as of the Restatement Date, this Restated Agreement constitutes the entire agreement between
the parties regarding the subject matter hereof, and supersedes all prior or contemporaneous understandings oi agreements regarding
the subject matter hereof, whether oral or written, including the 2017 Agreement; provided, however, that if this Restated
Agreement is terminated in accordance with Section 7.1, then the 2017 Agreement shall be deemed to have been continuously in effect
after the Restatement Date and shall remain in full force and effect in accordance with its terms. This Restated Agreement shall
be modified or amended only by a writing specifically referring to this Restated Agreement signed by both Eton and Eyemax.

 

9.10
Force Majeure. Neither party shall be liable for delays in its performance caused by Force Majeure Events, provided the
affected party gives the other party written notice of such event [* * *]
days of its occurrence. Such notice shall state the estimated duration of such event and the cause thereof and the affected party
shall use commercially reasonable efforts to work around such event beyond its control.

 

9.11
Headings and Construction. No rule of construction shall be applied to the disadvantage of a party because that party was
responsible for the preparation of this Restated Agreement or any part of this Restated Agreement. The Article and Section headings
in this Restated Agreement are for convenient reference only and shall be given no substantive or interpretive effect. With respect
to all terms used in this Restated Agreement, words used in the singular include the plural and words used in the plural include
the singular. The word ‘including’ means including without limitation, and the words ‘herein’, ‘hereby’,
‘hereto ‘and ‘hereunder’ refer to this Restated Agreement as a whole. Unless the context otherwise requires,
references found in this Restated Agreement: (i) to Articles and Sections mean the Articles and Sections of this Restated Agreement,
as amended, supplemented and modified from time to time; (ii) to an agreement, instrument or other document means such agreement;
(iii) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented
and modified from time to time, to the extent provided by the provisions thereof and by this Restated Agreement; and (iv) to a
statute or a regulation mean such statute or regulation as amended from time to time.

 

[Remainder
of Page Intentionally Left Blank]

 

    	 	28	 

    	 

    

 

IN
WITNESS WHEREOF, each party has caused a duly authorized representative to execute this Restated Agreement as of the Restatement
Date.

 

	 	EYEMAX
    LLC
	 	 	 
	 	By:	
	 	Name:	Elias
    Reichel
	 	Title:	President

 

	 	ETON
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	                                    
	 	Name:	Sean
    Brynjelsen
	 	Title:	CEO

 

IN
WITNESS WHEREOF, each party has caused a duly authorized representative to execute this Restated Agreement as of the Restatement
Date.

 

	 	EYEMAX
    LLC
	 	 	 
	 	By:	                                      
	 	Name:	Elias
    Reichel
	 	Title:	President

 

	 	ETON
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	
	 	Name:	Sean
    Brynjelsen
	 	Title:	CEO

 

    	 	 	 

    	 

    

 

Section
4.1. Exhibit A

 

[*
* *]

 

    	 	 	 

    	 

    

 

Section
4.2. Exhibit B

 

[*
* *]EXHIBIT 4.1

 

SPIRIT AEROSYSTEMS, INC.

 

INDENTURE

 

Dated as of [  ], 2019

 

THE BANK OF NEW YORK

 

MELLON TRUST COMPANY, N.A., TRUSTEE

 

 

CROSS-REFERENCE TABLE*

 

	
Trust Indenture
   Act Section
    	
 
    	
Indenture
   Section
    
	
310(a)(1)
    	
 
    	
7.10
    
	
(a)(2)
    	
 
    	
7.10
    
	
(a)(3)
    	
 
    	
N.A.
    
	
(a)(4)
    	
 
    	
N.A.
    
	
(a)(5)
    	
 
    	
7.10
    
	
(b)
    	
 
    	
7.10
    
	
(c)
    	
 
    	
N.A.
    
	
311(a)
    	
 
    	
7.11
    
	
(b)
    	
 
    	
7.11
    
	
(c)
    	
 
    	
N.A.
    
	
312(a)
    	
 
    	
2.06
    
	
(b)
    	
 
    	
11.03
    
	
(c)
    	
 
    	
11.03
    
	
313(a)
    	
 
    	
7.06
    
	
(b)(2)
    	
 
    	
7.06;
    
	
 
    	
 
    	
7.07
    
	
(c)
    	
 
    	
7.06;
    
	
 
    	
 
    	
11.02
    
	
(d)
    	
 
    	
7.06
    
	
314(a)
    	
 
    	
4.03;
    
	
 
    	
 
    	
4.04;
    
	
 
    	
 
    	
11.02
    
	
(b)
    	
 
    	
N.A.
    
	
(c)(l)
    	
 
    	
11.04
    
	
(c)(2)
    	
 
    	
11.04
    
	
(c)(3)
    	
 
    	
N.A.
    
	
(d)
    	
 
    	
N.A.
    
	
(e)
    	
 
    	
11.05
    
	
(f)
    	
 
    	
N.A.
    
	
315(a)
    	
 
    	
7.01
    
	
(b)
    	
 
    	
7.05;
    
	
 
    	
 
    	
11.02
    
	
(c)
    	
 
    	
7.01
    
	
(d)
    	
 
    	
7.01
    
	
(e)
    	
 
    	
6.11
    
	
316(a) (last sentence)
    	
 
    	
2.10
    
	
(a)(l)(A)
    	
 
    	
6.05
    
	
(a)(l)(B)
    	
 
    	
6.04
    
	
(a)(2)
    	
 
    	
N.A.
    
	
(b)
    	
 
    	
6.07
    
	
(c)
    	
 
    	
2.14
    
	
317(a)(l)
    	
 
    	
6.08
    
	
(a)(2)
    	
 
    	
6.09
    

 

i

 

	
Trust Indenture
   Act Section
    	
 
    	
Indenture
   Section
    
	
(b)
    	
 
    	
2.05
    
	
318(a)
    	
 
    	
11.01
    
	
(b)
    	
 
    	
N.A.
    
	
(c)
    	
 
    	
11.01
    

 

N.A. means not applicable.

 

*                                         This Cross Reference Table is not part of this Indenture.

 

ii

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
ARTICLE I   DEFINITIONS AND INCORPORATION BY REFERENCE
    	
1
    
	
Section 1.01
    	
Definitions
    	
1
    
	
Section 1.02
    	
Other Definitions
    	
6
    
	
Section 1.03
    	
Incorporation by   Reference of Trust Indenture Act
    	
6
    
	
Section 1.04
    	
Rules of   Construction
    	
7
    
	
 
    	
 
    	
 
    
	
ARTICLE II   THE NOTES
    	
7
    
	
Section 2.01
    	
Issuable in Series
    	
7
    
	
Section 2.02
    	
Establishment of Terms   of Series of Notes
    	
7
    
	
Section 2.03
    	
Execution and   Authentication
    	
9
    
	
Section 2.04
    	
Registrar and Paying   Agent
    	
10
    
	
Section 2.05
    	
Paying Agent to Hold   Money in Trust
    	
11
    
	
Section 2.06
    	
Holder Lists
    	
11
    
	
Section 2.07
    	
Transfer and Exchange
    	
11
    
	
Section 2.08
    	
Replacement Notes
    	
12
    
	
Section 2.09
    	
Outstanding Notes
    	
12
    
	
Section 2.10
    	
Treasury Notes
    	
13
    
	
Section 2.11
    	
Temporary Notes
    	
13
    
	
Section 2.12
    	
Cancellation
    	
13
    
	
Section 2.13
    	
Defaulted Interest
    	
13
    
	
Section 2.14
    	
Global Notes
    	
14
    
	
Section 2.15
    	
CUSIP Number
    	
16
    
	
 
    	
 
    	
 
    
	
ARTICLE III   REDEMPTION AND PREPAYMENT
    	
16
    
	
Section 3.01
    	
Notice to Trustee
    	
16
    
	
Section 3.02
    	
Selection of Notes to   Be Redeemed
    	
16
    
	
Section 3.03
    	
Notice of Redemption
    	
17
    
	
Section 3.04
    	
Effect of Notice of   Redemption
    	
18
    
	
Section 3.05
    	
Deposit of Redemption   Price
    	
18
    
	
Section 3.06
    	
Notes Redeemed in Part
    	
18
    
	
 
    	
 
    	
 
    
	
ARTICLE IV   COVENANTS
    	
18
    
	
Section 4.01
    	
Payment of Principal   and Interest
    	
18
    
	
Section 4.02
    	
Maintenance of Office   or Agency
    	
18
    
	
Section 4.03
    	
Reports
    	
19
    
	
Section 4.04
    	
Compliance Certificate
    	
19
    
	
Section 4.05
    	
Taxes
    	
19
    
	
Section 4.06
    	
Stay, Extension and   Usury Laws
    	
19
    
	
Section 4.07
    	
Corporate Existence
    	
20
    
	
 
    	
 
    	
 
    
	
ARTICLE V   SUCCESSORS
    	
20
    
	
Section 5.01
    	
Merger, Consolidation,   or Sale of Assets
    	
20
    
	
Section 5.02
    	
Successor Corporation   Substituted
    	
21
    
				

 

iii

 

	
ARTICLE VI   DEFAULTS AND REMEDIES
    	
 21
    
	
Section 6.01
    	
Events of Default
    	
21
    
	
Section 6.02
    	
Acceleration
    	
22
    
	
Section 6.03
    	
Other Remedies
    	
23
    
	
Section 6.04
    	
Waiver of Past Defaults
    	
23
    
	
Section 6.05
    	
Control by Majority
    	
23
    
	
Section 6.06
    	
Limitation on Suits
    	
24
    
	
Section 6.07
    	
Rights of Holders of   Notes to Receive Payment
    	
24
    
	
Section 6.08
    	
Collection Suit by   Trustee
    	
24
    
	
Section 6.09
    	
Trustee May File   Proofs of Claim
    	
24
    
	
Section 6.10
    	
Priorities
    	
25
    
	
Section 6.11
    	
Undertaking for Costs
    	
25
    
	
Section 6.12
    	
Restoration of Rights   and Remedies
    	
25
    
	
Section 6.13
    	
Waiver of Stay,   Extension or Usury Laws
    	
26
    
	
 
    	
 
    	
 
    
	
ARTICLE VII   TRUSTEE
    	
26
    
	
Section 7.01
    	
Duties of Trustee
    	
26
    
	
Section 7.02
    	
Rights of Trustee
    	
27
    
	
Section 7.03
    	
Individual Rights of   Trustee
    	
29
    
	
Section 7.04
    	
Trustee’s Disclaimer
    	
29
    
	
Section 7.05
    	
Notice of Defaults
    	
29
    
	
Section 7.06
    	
Reports by Trustee to   Holders of the Notes
    	
30
    
	
Section 7.07
    	
Compensation and   Indemnity
    	
30
    
	
Section 7.08
    	
Replacement of Trustee
    	
31
    
	
Section 7.09
    	
Successor Trustee by   Merger, etc.
    	
32
    
	
Section 7.10
    	
Eligibility;   Disqualification
    	
32
    
	
Section 7.11
    	
Preferential Collection   of Claims Against Company
    	
32
    
	
 
    	
 
    	
 
    
	
ARTICLE VIII   LEGAL DEFEASANCE AND COVENANT DEFEASANCE
    	
33
    
	
Section 8.01
    	
Option to Effect Legal   Defeasance or Covenant Defeasance
    	
33
    
	
Section 8.02
    	
Legal Defeasance and   Discharge
    	
33
    
	
Section 8.03
    	
Covenant Defeasance
    	
33
    
	
Section 8.04
    	
Conditions to Legal or   Covenant Defeasance
    	
34
    
	
Section 8.05
    	
Deposited Money and   Government Securities to be Held in Trust; Other Miscellaneous Provisions
    	
35
    
	
Section 8.06
    	
Repayment to Company
    	
36
    
	
Section 8.07
    	
Reinstatement
    	
36
    
	
 
    	
 
    	
 
    
	
ARTICLE IX   AMENDMENT, SUPPLEMENT AND WAIVER
    	
36
    
	
Section 9.01
    	
Without Consent of   Holders of Notes
    	
36
    
	
Section 9.02
    	
With Consent of Holders   of Notes
    	
37
    
	
Section 9.03
    	
Compliance with Trust   Indenture Act
    	
38
    
	
Section 9.04
    	
Revocation and Effect   of Consents
    	
39
    
	
Section 9.05
    	
Notation on or Exchange   of Notes
    	
39
    
	
Section 9.06
    	
Trustee to Sign   Amendments, etc.
    	
39
    

 

iv

 

	
ARTICLE X   SATISFACTION AND DISCHARGE
    	
39
    
	
Section 10.01
    	
Satisfaction and   Discharge
    	
39
    
	
Section 10.02
    	
Application of Trust   Money
    	
40
    
	
 
    	
 
    	
 
    
	
ARTICLE XI   MISCELLANEOUS
    	
41
    
	
Section 11.01
    	
Trust Indenture Act   Controls
    	
41
    
	
Section 11.02
    	
Notices
    	
41
    
	
Section 11.03
    	
Communication by   Holders of Notes with Other Holders of Notes
    	
42
    
	
Section 11.04
    	
Certificate and Opinion   as to Conditions Precedent
    	
43
    
	
Section 11.05
    	
Statements Required in   Certificate or Opinion
    	
43
    
	
Section 11.06
    	
Rules by Trustee   and Agents
    	
43
    
	
Section 11.07
    	
Calculation of Foreign   Currency Amounts
    	
43
    
	
Section 11.08
    	
No Personal Liability   of Directors, Officers, Employees and Shareholders
    	
43
    
	
Section 11.09
    	
Governing Law;   Submission to Jurisdiction
    	
44
    
	
Section 11.10
    	
No Adverse   Interpretation of Other Agreements
    	
44
    
	
Section 11.11
    	
Successors
    	
44
    
	
Section 11.12
    	
Severability
    	
44
    
	
Section 11.13
    	
Counterpart Originals
    	
44
    
	
Section 11.14
    	
Table of Contents,   Headings, etc.
    	
44
    
	
Section 11.15
    	
Waiver of Jury Trial
    	
45
    
	
Section 11.16
    	
Patriot Act Compliance
    	
45
    

 

v

 

INDENTURE, dated as of [  ], 2019, by and between Spirit AeroSystems, Inc., a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., a national banking association organized and existing under the laws of the United States of America, as trustee (the “Trustee”).

 

The Company and the Trustee agree as follows for the benefit of each other and for the equal and ratable benefit of the Holders of the Notes (as defined below) issued under this Indenture.

 

ARTICLE I

 

DEFINITIONS AND INCORPORATION BY REFERENCE

 

Section 1.01                Definitions.

 

“Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person.  For purposes of this definition, “control,” as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise.  For purposes of this definition, the terms “controlling,” “controlled by” and “under common control with” have correlative meanings.

 

“Agent” means any Registrar, co-registrar, Custodian, Paying Agent or additional paying agent.

 

“Applicable Procedures” means, with respect to any payment, tender, redemption, transfer, exchange, or conversion of or for beneficial interests in any Global Note, the rules and procedures of the Depositary that apply to such payment, tender, redemption, transfer, exchange, or conversion.

 

“Bankruptcy Law” means Title 11, U.S. Code or any similar federal or state law for the relief of debtors.

 

“Board of Directors” means:

 

(1)           with respect to a corporation, the board of directors of the corporation or any committee thereof duly authorized to act on behalf of such board;

 

(2)           with respect to a partnership, the Board of Directors of the general partner of the partnership;

 

(3)           with respect to a limited liability company, the managing member or members or any controlling committee of managing members thereof; and

 

(4)           with respect to any other Person, the board or committee of such Person serving a similar function.

 

1

 

“Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to the Trustee.

 

“Business Day” means any day other than a Legal Holiday.  If a payment date falls on a day that is not a Business Day, the related payment shall be made on the next succeeding Business Day as if made on the date the payment is due, and no interest shall accrue on such payment for the intervening period.

 

“Capital Lease Obligation” means, at the time any determination is to be made, the amount of the liability in respect of a capital lease that would at that time be required to be capitalized on a balance sheet prepared in accordance with GAAP.

 

“Capital Stock” means:

 

(1)           in the case of a corporation, corporate stock;

 

(2)           in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock;

 

(3)           in the case of a partnership or limited liability company, partnership interests (whether general or limited) or membership interests; and

 

(4)           any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person.

 

“Company” means Spirit AeroSystems, Inc., and, subject to Article V, any and all successors thereto.

 

“Company Order” means a written order signed in the name of the Company by an Officer.

 

“Corporate Trust Office of the Trustee” means the designated office of the Trustee at which at any time its corporate trust business in respect of this Indenture shall be administered, which office at the date hereof is located at 2 North LaSalle Street, 7th Floor, Chicago, Illinois 60602, Attention:  Corporate Finance Unit, except that with respect to presentation of the Notes for payment or for registration of transfer or exchange, such term shall mean the office or agency of the Trustee at which at any particular time its corporate agency business shall be conducted, which office at the date of this instrument is located at 240 Greenwich Street, New York, New York 10286; Attention:  Corporate Trust Division - Corporate Finance Unit, or, in the case of any of such offices or agency, such other address as the Trustee may designate from time to time by notice to the Holders and the Company, or the principal corporate trust office of any successor Trustee (or such other address as such successor Trustee may designate from time to time by notice to the Holders and the Company).

 

“Custodian” means the Trustee, as custodian for the Depositary with respect to any Global Notes, or any successor entity thereto.

 

2

 

“Default” means any event that is, or with the passage of time or the giving of notice or both would be, an Event of Default.

 

“Depositary” means, with respect to the Notes of any Series issuable or issued in whole or in part in the form of one or more Global Notes, the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency registered under the Exchange Act; and if at any time there is more than one such person, “Depositary” as used with respect to the Notes of any Series shall mean the Depositary with respect to the Notes of such Series.

 

“Discount Note” means any Note that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.02.

 

“Dollars” and “$” means the currency of The United States of America.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Foreign Currency” means any currency or currency unit issued by a government other than the government of The United States of America.

 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of this Indenture.

 

“Global Note” or “Global Notes” means a Note or Notes, as the case may be, in the form established pursuant to Section 2.02 evidencing all or part of a Series of Notes, issued to the Depositary for such Series or its nominee, and registered in the name of such Depositary or nominee.

 

“Government Securities” means direct obligations of, or obligations guaranteed by, The United States of America, and the payment for which the United States pledges its full faith and credit.

 

“Guarantee” means a guarantee other than by endorsement of negotiable instruments for collection in the ordinary course of business, direct or indirect, in any manner including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, of all or any part of any Indebtedness.

 

“Hedging Obligations” means, with respect to any specified Person, the obligations of such Person under:

 

(1)           interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements;

 

3

 

(2)           other agreements or arrangements designed to manage interest rates or interest rate risk; and

 

(3)           other agreements or arrangements designed to protect such Person against fluctuations in currency exchange rates or commodity prices.

 

“Holder” means a Person in whose name a Note is registered.

 

“Indebtedness” means, with respect to any specified Person, any indebtedness of such Person, whether or not contingent:

 

(1)           in respect of borrowed money;

 

(2)           evidenced by bonds, notes, debentures or similar instruments or letters of credit, or reimbursement agreements in respect thereof;

 

(3)           in respect of banker’s acceptances;

 

(4)           representing Capital Lease Obligations;

 

(5)           representing the balance deferred and unpaid of the purchase price of any property, except any such balance that constitutes an accrued expense or trade payable; or

 

(6)           representing any Hedging Obligations,

 

if and to the extent any of the preceding items, other than letters of credit and Hedging Obligations, would appear as a liability upon a balance sheet of the specified Person prepared in accordance with GAAP.  In addition, the term “Indebtedness” includes all Indebtedness of others secured by a Lien on any asset of the specified Person, whether or not such Indebtedness is assumed by the specified Person, and, to the extent not otherwise included, the Guarantee by the specified Person of any Indebtedness of any other Person or any liability of any person, whether or not contingent and whether or not it appears on the balance sheet of such Person.

 

The amount of any Indebtedness outstanding as of any date shall be:

 

(1)           the accreted value of the Indebtedness, in the case of any Indebtedness that does not require the current payment of interest; and

 

(2)           the principal amount of the Indebtedness, together with any interest on the Indebtedness that is more than 30 days past due, in the case of any other Indebtedness.

 

“Indenture” means this Indenture, as amended, supplemented or restated from time to time and shall include the form and terms of particular Series of Notes established as contemplated hereunder.

 

“Legal Holiday” means a Saturday, a Sunday or a day on which banking institutions in the City of New York, the city of Wichita, Kansas or the city where the Corporate Trust Office

 

4

 

of the Trustee is located at such time are required or authorized by law, regulation or executive order to close or be closed.

 

“Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law, including any conditional sale or other title retention agreement, any lease in the nature thereof, any option or other agreement to sell or give a security interest in and any filing of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statutes) of any jurisdiction; provided that in no event shall an operating lease be deemed to constitute a Lien.

 

“Notes” means notes or other debt instruments of the Company of any Series issued under this Indenture.

 

“Officer” means, with respect to any Person, the Chief Executive Officer, the President, the Chief Operating Officer, the Chief Financial Officer, the Treasurer, any Assistant Treasurer, the Controller, the Secretary, the Assistant Secretary or any Vice-President of such Person.

 

“Officer’s Certificate” means a certificate signed by an Officer of the Company that meets the requirements of Section 11.05 hereof, and delivered to the Trustee.

 

“Opinion of Counsel” means an opinion from legal counsel, who may be an employee of or counsel to the Company or any Subsidiary of the Company, or other counsel reasonably acceptable to the Trustee, that meets the requirements of Section 11.05 hereof.

 

“Person” means any individual, corporation, partnership, joint venture, association, joint-stock company, trust, unincorporated organization, limited liability company or government or other entity.

 

“Responsible Officer,” when used with respect to the Trustee, means any director, vice president, assistant vice president or associate within the Corporate Trust Office of the Trustee (or any successor group of the Trustee) or any other officer of the Trustee customarily performing functions similar to those performed by any of the above designated officers who at the time shall have direct responsibility for the administration of this Indenture and also means, with respect to a particular corporate trust matter, any other officer to whom such matter is referred because of his knowledge of and familiarity with the particular subject.

 

“SEC” means the Securities and Exchange Commission.

 

“Securities Act” means the Securities Act of 1933, as amended.

 

“Series” or “Series of Notes” means each series of debentures, notes or other debt instruments of the Company created pursuant to Sections 2.01 and 2.02 hereof.

 

“Stated Maturity” means, with respect to any installment Indebtedness, the date specified as the fixed date on which the final payment of principal was scheduled to be paid in the documentation governing such Indebtedness, and will not include any contingent obligations to

 

5

 

repay, redeem or repurchase any such principal prior to the date originally scheduled for the payment thereof.

 

“Subsidiary” means:

 

(1)           any corporation, association or other business entity of which more than 50% of the outstanding Voting Stock is owned or controlled, directly or indirectly, by the Company or by one or more Subsidiaries of the Company; and

 

(2)           any partnership (a) the sole general partner or the managing general partner of which is the Company or a Subsidiary of the Company or (b) the only general partners of which are the Company or one or more Subsidiaries of the Company (or any combination thereof).

 

“TIA” means the Trust Indenture Act of 1939, as amended (15 U.S.C. §§ 77aaa-77bbbb).

 

“Trustee” means the person named as the “Trustee” in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean each person who is then a Trustee hereunder, and if at any time there is more than one such person, “Trustee” as used with respect to the Notes of any Series shall mean the Trustee with respect to Notes of that Series.

 

“Voting Stock” of any specified Person as of any date means the Capital Stock of such Person that is at the time entitled to vote in the election of the Board of Directors of such Person.

 

Section 1.02                Other Definitions.

 

	
Term
    	
 
    	
Defined
   in
   Section
    	
 
    
	
“Authentication   Order”
    	
 
    	
2.03
    	
 
    
	
“Covenant Defeasance”
    	
 
    	
8.03
    	
 
    
	
“Event of   Default”
    	
 
    	
6.01
    	
 
    
	
“Legal   Defeasance”
    	
 
    	
8.02
    	
 
    
	
“Paying Agent”
    	
 
    	
2.04
    	
 
    
	
“Registrar”
    	
 
    	
2.04
    	
 
    

 

Section 1.03                Incorporation by Reference of Trust Indenture Act.  Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture.

 

The following TIA terms used in this Indenture have the following meanings:

 

“indenture securities” means the Notes;

 

“indenture security Holder” means a Holder of a Note;

 

“indenture to be qualified” means this Indenture;

 

6

 

“indenture trustee” or “institutional trustee” means the Trustee; and

 

“obligor” on the indenture securities means the Company, and any other obligor upon the Notes.

 

All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under the TIA have the meanings so assigned to them.

 

Section 1.04                Rules of Construction.  Unless the context otherwise requires:

 

(1)           a term has the meaning assigned to it;

 

(2)           an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;

 

(3)           “or” is not exclusive;

 

(4)           words in the singular include the plural, and in the plural include the singular;

 

(5)           “will” shall be interpreted to express a command;

 

(6)           provisions apply to successive events and transactions; and

 

(7)           references to sections of or rules under the Securities Act will be deemed to include substitute, replacement or successor sections or rules adopted by the SEC from time to time.

 

ARTICLE II

 

THE NOTES

 

Section 2.01                Issuable in Series.  The aggregate principal amount of Notes that may be authenticated and delivered under this Indenture is unlimited.  The Notes may be issued in one or more Series.  All Notes of a Series shall be identical except as may be set forth in a Board Resolution, a supplemental indenture or an Officer’s Certificate detailing the adoption of the terms thereof pursuant to the authority granted under a Board Resolution.  In the case of Notes of a Series to be issued from time to time, the Board Resolution, Officer’s Certificate or supplemental indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are to be determined.  Notes may differ between Series in respect of any matters, provided that all Series of Notes shall be equally and ratably entitled to the benefits of this Indenture.

 

Section 2.02                Establishment of Terms of Series of Notes.  At or prior to the issuance of any Notes within a Series, the following shall be established (as to the Series generally, in the case of Subsection 2.02(a) and either as to such Notes within the Series or as to the Series

 

7

 

generally in the case of Subsections 2.02(b) through 2.02(r)) by or pursuant to a Board Resolution, and set forth or determined in the manner provided in a Board Resolution, supplemental indenture or an Officer’s Certificate pursuant to authority granted under a Board Resolution:

 

(a)           the title of the Series (which shall distinguish the Notes of that particular Series from the Notes of any other Series);

 

(b)           the price or prices (expressed as a percentage of the principal amount thereof) at which the Notes of the Series will be issued;

 

(c)           any limit upon the aggregate principal amount of the Notes of the Series which may be authenticated and delivered under this Indenture (except for Notes authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Notes of the Series pursuant to Section 2.07, 2.08, 2.11, 3.06 or 9.05);

 

(d)           the date or dates on which the principal of the Notes of the Series is payable;

 

(e)           the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including, but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Notes of the Series shall bear interest, if any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if any, shall commence and be payable and any regular record date for the interest payable on any interest payment date;

 

(f)            the place or places where the principal of, premium and interest, if any, on the Notes of the Series shall be payable, where the Notes of such Series may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Notes of such Series and this Indenture may be served, and the method of such payment, if by wire transfer, mail or other means;

 

(g)           if applicable, the period or periods within which, the price or prices at which and the terms and conditions upon which the Notes of the Series may be redeemed, in whole or in part, at the option of the Company;

 

(h)           the obligation, if any, of the Company to redeem or purchase the Notes of the Series pursuant to any sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Notes of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;

 

(i)            the dates, if any, on which and the price or prices at which the Notes of the Series will be repurchased by the Company at the option of the Holders thereof and other detailed terms and provisions of such repurchase obligations;

 

(j)            the denominations in which the Notes of the Series shall be issuable, if other than minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof;

 

8

 

(k)           the forms of the Notes of the Series in bearer or fully registered form (and, if in fully registered form, whether the Notes will be issuable as Global Notes);

 

(l)            if other than the principal amount thereof, the portion of the principal amount of the Notes of the Series that shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.02;

 

(m)          whether the Note of any Series will be “original issue discount” securities for U.S. federal income tax purposes;

 

(n)           the designation of the currency, currencies or currency units in which payment of the principal of, premium and interest, if any, on the Notes of the Series will be made if other than U.S. dollars;

 

(o)           the provisions, if any, relating to any security provided for the Notes of the Series, and any subordination in right of payment, if any, of the Notes of the Series;

 

(p)           any addition to or change in the Events of Default which applies to any Notes of the Series and any change in the right of the Trustee or the requisite Holders of such Notes to declare the principal amount thereof due and payable pursuant to Section 6.02;

 

(q)           any addition to or change in the covenants set forth in Articles IV or V that applies to Notes of the Series;

 

(r)            selling restrictions applicable to any Series of Notes, if any;

 

(s)            any other terms of the Notes of the Series (which may modify or delete any provision of this Indenture insofar as it applies to such Series); and

 

(t)            any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to Notes of such Series if other than those appointed herein.

 

All Notes of any one Series need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officer’s Certificate referred to above, and, unless otherwise provided, a Series may be reopened, without the consent of the Holders, for issuances of additional Notes of such Series; provided, however, that if such additional Notes are not issued in a “qualified reopening” within the meaning of Treasury Regulation section 1.1275-2(k)(3), the additional Notes will have a separate CUSIP number.  No Board Resolution or Officer’s Certificate may affect the Trustee’s own rights, duties or immunities under this Indenture or otherwise with respect to any series of Notes except as it may agree in writing.

 

Section 2.03                Execution and Authentication.  One Officer shall sign the Notes for the Company by manual or facsimile signature.  If an Officer whose signature is on a Note no longer holds that office at the time such Note is authenticated, such Note shall nevertheless be valid.

 

9

 

A Note shall not be valid until authenticated by the manual signature of the Trustee.  The signature shall be conclusive evidence that the Note, as applicable, has been authenticated under this Indenture.

 

The Trustee shall, upon a written order of the Company signed by one Officer (an “Authentication Order”), authenticate Notes for original issue in accordance with this Indenture.  The Notes shall be dated their date of authentication.  An Authentication Order shall specify the amount of Notes to be authenticated and the date on which the original issue of Notes is to be authenticated.

 

The Trustee may appoint an authenticating agent acceptable to the Company to authenticate Notes.  An authenticating agent may authenticate Notes whenever the Trustee may do so.  Each reference in this Indenture to authentication by the Trustee includes authentication by such agent.  An authenticating agent has the same rights as an Agent to deal with Holders or an Affiliate of the Company.

 

At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Notes of any Series executed by the Company to the Trustee for authentication, together with an Authentication Order for the authentication and delivery of such Notes, and the Trustee in accordance with such Authentication Order will authenticate and deliver such Notes.  In authenticating such Notes, and accepting the additional responsibilities under this Indenture in relation to such Notes, the Trustee shall receive, and (subject to Section 7.01) will be fully protected in relying upon, an Opinion of Counsel stating:

 

(a)           that such form has been established in conformity with the provisions of this Indenture;

 

(b)           that such terms have been established in conformity with the provisions of this Indenture; and

 

(c)           that the Indenture and such Notes, when authenticated and delivered by the Trustee and, with respect to the Notes, when issued by the Company, in the manner and subject to any conditions specified in such Opinion of Counsel, will constitute valid and binding obligations of the Company enforceable in accordance with their terms, except as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization, moratorium, or other laws relating to or affecting creditors’ rights and by general principles of equity.

 

Section 2.04                Registrar and Paying Agent.  The Company shall maintain an office or agency where Notes may be presented for registration of transfer or for exchange (“Registrar”) and an office or agency where Notes may be presented for payment (“Paying Agent”).  The Registrar shall keep a register with respect to each Series of the Notes and of their transfer and exchange.  The Company may appoint one or more co-registrars and one or more additional paying agents or change the office of such Registrar or Paying Agent.  The term “Registrar” includes any co-registrar and the term “Paying Agent” includes any additional paying agent.  The Company may change any Paying Agent or Registrar without notice to any Holder; however, the Company shall maintain a Paying Agent in each place of payment for the Notes of each Series.  The Company shall notify the Trustee in writing of the name and address of any Agent not a

 

10

 

party to this Indenture.  If the Company fails to appoint or maintain another entity as Registrar or Paying Agent, the Trustee shall act as such.  The Company or any of its Subsidiaries may act as Paying Agent or Registrar.

 

The Company initially appoints the Trustee to act as the Registrar and Paying Agent and to act as Custodian with respect to the Global Notes.  The Company shall be responsible for making calculations called for under the Notes and this Indenture, including, but not limited to, determination of interest, additional amounts, redemption price, premium, if any, and any other amounts payable on the Notes.  The Company will make the calculations in good faith and, absent manifest error, its calculations will be final and binding on the Holders.  The Company will provide a schedule of its calculations to the Trustee when requested by the Trustee in writing, and the Trustee is entitled to rely conclusively on the accuracy of the Company’s calculations without independent verification.  The Trustee shall forward the Company’s calculations to any Holder of the Notes upon the written request of such Holder.

 

Section 2.05                                                Paying Agent to Hold Money in Trust.  The Company shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Holders of any Series of Notes, or the Trustee, all money held by the Paying Agent for the payment of principal, premium, if any, or interest on the Series of Notes, and shall notify the Trustee of any default by the Company in making any such payment.  While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee.  The Company at any time may require a Paying Agent to pay all money held by it to the Trustee.  All payments to a Paying Agent on any Notes which remain unclaimed for a period of two years after such payment was due shall be repaid to the Company.  Thereafter, the Holder may look only to the Company for repayment.  Upon payment over to the Trustee, or to the Company, as the case may be, the Paying Agent (if other than the Company or a Subsidiary) shall have no further liability for such money.  If the Company or a Subsidiary acts as Paying Agent, it shall segregate and hold in a separate trust fund for the benefit of Holders of any Series of Notes all money held by it as Paying Agent.  Upon any Event of Default under Sections 6.01(d) and (e) hereof relating to the Company, the Trustee shall serve as Paying Agent for the Notes.

 

Section 2.06                                                Holder Lists.  The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Holders of each Series of Notes and shall otherwise comply with TIA Section 312(a).  If the Trustee is not the Registrar, the Company shall furnish to the Trustee, at least two Business Days before each interest payment date and at such other times as the Trustee may request in writing, a list in such form and as of such date as the Trustee may reasonably require of the names and addresses of Holders of each Series of Notes and the Company shall otherwise comply with TIA Section 312(a).

 

Section 2.07                                                Transfer and Exchange.  Notes may be transferred or exchanged at the office of the Registrar or co-registrar designated by the Company.  Where Notes of a Series are presented to the Registrar or a co-registrar with a request to register a transfer or to exchange them for an equal principal amount of Notes of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met.  To permit registrations of transfers and exchanges, the Trustee shall authenticate Notes at the Registrar’s

 

11

 

request.  No service charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than any such transfer tax or similar governmental charge payable upon exchanges pursuant to Section 2.11, 3.06 or 9.05).

 

Neither the Company nor the Registrar shall be required (a) to issue, register the transfer of, or exchange Notes of any Series for the period beginning at the opening of business fifteen days immediately preceding the mailing of a notice of redemption of Notes of that Series selected for redemption and ending at the close of business on the day of such mailing, or (b) to register the transfer of or exchange Notes of any Series selected, called or being called for redemption as a whole or a portion thereof, except the unredeemed portion of Notes being redeemed in part.

 

The Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among Depositary participants or beneficial owners of interests in any Global Note) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express requirements hereof.

 

Section 2.08                                                Replacement Notes.  If any mutilated Note is surrendered to the Trustee, or if the Company and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Note, the Company shall issue and the Trustee, upon receipt of an Authentication Order together with such indemnity and/or security sufficient in the judgment of the Trustee and the Company to protect the Company, the Trustee, any Agent and any authenticating agent from any loss that any of them may suffer if a Note is replaced, shall authenticate a replacement Note of the same Series if the Trustee’s requirements are met.  The Company and the Trustee may charge for its expenses in replacing a Note.

 

Every replacement Note of any Series is an additional obligation of the Company and shall be entitled to all of the benefits of this Indenture equally and proportionately with all other Notes of that Series duly issued hereunder.

 

Section 2.09                                                Outstanding Notes.  The Notes outstanding at any time are all the Notes authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation, those reductions in the interest in a Global Note effected by the Trustee in accordance with the provisions hereof, and those described in this Section as not outstanding.  Except as set forth in Section 2.10 hereof, a Note does not cease to be outstanding because the Company or an Affiliate of the Company holds the Note.

 

If a Note is replaced pursuant to Section 2.08 hereof, it ceases to be outstanding unless the Trustee receives proof satisfactory to it that the replaced Note is held by a bona fide purchaser.

 

12

 

If the principal amount of any Note is considered paid under Section 4.01 hereof, it ceases to be outstanding and interest on it ceases to accrue.

 

If the Paying Agent (other than the Company, a Subsidiary or an Affiliate of any thereof) holds, on a redemption date or maturity date, money sufficient to pay Notes payable on that date, then on and after that date such Notes shall be deemed to be no longer outstanding and shall cease to accrue interest.

 

Section 2.10                                                Treasury Notes.  In determining whether the Holders of the required principal amount of Notes of a Series have concurred in any direction, waiver or consent, Notes owned by the Company, or by an Affiliate of the Company, shall be considered as though not outstanding, except that for the purposes of determining whether the Trustee shall be protected in relying on any such direction, waiver or consent, only Notes of a Series that a Responsible Officer of the Trustee actually knows are so owned shall be so disregarded.

 

Section 2.11                                                Temporary Notes.  Until certificates representing Notes are ready for delivery, the Company may prepare and the Trustee, upon receipt of an Authentication Order, shall authenticate temporary Notes.  Temporary Notes shall be substantially in the form of certificated Notes but may have variations that the Company considers appropriate for temporary Notes and as shall be reasonably acceptable to the Trustee.  Without unreasonable delay, the Company shall prepare and the Trustee shall authenticate definitive Notes in exchange for temporary Notes.

 

Holders of temporary Notes shall be entitled to all of the benefits of this Indenture.

 

Section 2.12                                                Cancellation.  The Company at any time may deliver Notes to the Trustee for cancellation.  The Registrar and Paying Agent shall forward to the Trustee any Notes surrendered to them for registration of transfer, exchange or payment.  The Trustee and no one else shall cancel all Notes surrendered for registration of transfer, exchange, payment, replacement or cancellation.  The Company may not issue new Notes to replace Notes that it has paid or that have been delivered to the Trustee for cancellation.  Cancelled Notes shall be disposed of by the Trustee pursuant to its standard procedures and, upon request by the Company, the Trustee shall deliver a certificate or other evidence of such disposition.

 

Section 2.13                                                Defaulted Interest.  If the Company defaults in a payment of interest on a Series of Notes, it shall pay the defaulted interest in any lawful manner plus, to the extent lawful, interest payable on the defaulted interest, to the Persons who are Holders of the Series on a subsequent special record date, in each case at the rate provided in the Notes and in Section 4.01 hereof.  The Company shall notify the Trustee in writing of the amount of defaulted interest proposed to be paid on each Note and the date of the proposed payment.  The Company shall fix or cause to be fixed each such special record date and payment date, provided that no such special record date shall be less than 10 days prior to the related payment date for such defaulted interest.  At least 15 days before the special record date, the Company (or, upon the written request of the Company, the Trustee in the name and at the expense of the Company) shall mail or cause to be mailed (or, in the case of the Depositary with respect to any Global Note, sent

 

13

 

electronically) to Holders a notice that states the special record date, the related payment date and the amount of such interest to be paid.

 

Section 2.14                                                Global Notes.

 

(a)                                 Terms of Notes.  A Board Resolution, a supplemental indenture hereto, or an Officer’s Certificate shall establish whether the Notes of a Series shall be issued in whole or in part in the form of one or more Global Notes and shall name the Depositary for such Global Note or Notes.  Except as provided herein, each Global Note shall be (i) registered in the name of the Depositary, (ii) deposited with the Depositary or its nominee, and (iii) bear the legend indicated in Section 2.14(c).

 

(b)                                 Transfer and Exchange.  Notwithstanding any provisions to the contrary contained in Section 2.07, any Global Note shall be exchangeable pursuant to Section 2.07 for Notes registered in the names of Holders other than the Depositary for such Note or its nominee only if (i) such Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such Global Note or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in either case, the Company fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such event, (ii) the Company executes and delivers to the Trustee an Officer’s Certificate to the effect that such Global Note shall be so exchangeable or (iii) an Event of Default with respect to the Notes represented by such Global Note shall have occurred and be continuing.  Any Global Note that is exchangeable pursuant to the preceding sentence shall be exchangeable for Notes registered in such names as the Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the Global Note with like tenor and terms.

 

Except as provided in this Section 2.14(b), a Global Note may not be transferred except as a whole by the Depositary with respect to such Global Note to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary, or any such nominee to a successor Depositary or a nominee of such a successor Depositary.

 

(c)                                  Legend.  Any Global Note issued hereunder shall bear a legend in substantially the following form:

 

“This Note is a Global Note within the meaning of the Indenture hereinafter referred to and is registered in the name of the Depositary or a nominee of the Depositary.  This Note is exchangeable for Notes registered in the name of a person other than the Depositary or its nominee only in the limited circumstances described in the Indenture, and may not be transferred except as a whole by the Depositary to a nominee of the Depositary, by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such a successor Depositary.”

 

(d)                                 Acts of Holders.  The Depositary, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the

 

14

 

Indenture.  The record date for purposes of determining the identity of Holders entitled to vote or consent to any action by vote or consent authorized or permitted under this Indenture may be determined as provided for in Section 316(c) of the TIA.

 

(e)                                  Payments.  Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.02, payment of the principal of and interest, if any, on any Global Note shall be made to the Holder thereof.  Prior to due presentment of a Note for registration of transfer, the Company, the Trustee, and any agent of the Company or the Trustee may treat the Person in whose name such Note is registered as the owner of such Note at the close of business on the regular record date for the purpose of receiving payment of principal of and any premium and (subject to Section 2.13) any interest on such Note and for all other purposes whatsoever, whether or not such Security shall be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee will be affected by notice to the contrary.

 

(f)                                   Consents, Declaration and Directions.  Except as provided in Section 2.14(e), the Company, the Trustee and any Agent shall treat a person as the Holder of such principal amount of outstanding Notes of such Series represented by a Global Note as shall be specified in a written statement of the Depositary with respect to such Global Note, for purposes of obtaining any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture.

 

(g)                                  Responsibility of Trustee or Agents.  Neither the Trustee nor any Agent shall have any responsibility for any actions taken or not taken by the Depositary.  The Company has entered into a letter of representations with the Depositary in the form provided by the Depositary and the Trustee and each Agent is hereby authorized to act in accordance with such letter and the Applicable Procedures.

 

Neither the Trustee nor any Agent shall have any responsibility or obligation to any beneficial owner of a Global Note, a Depositary participant or other Person with respect to the accuracy of the records of the Depositary or its nominee or of any Depositary participant, with respect to any ownership interest in the Notes or with respect to the delivery to any Depositary participant, beneficial owner or other Person (other than the Depositary) of any notice (including any notice of redemption) or the payment of any amount, under or with respect to such Notes.  All notices and communications to be given to the Holders and all payments to be made to Holders under the Notes and this Indenture shall be given or made only to or upon the order of the registered holders (which shall be the Depositary or its nominee in the case of a Global Note).  The rights of a beneficial owner in a Global Note shall be exercised only through the Depositary subject to the Applicable Procedures.  The Trustee and the Agents shall be entitled to rely and shall be fully protected in relying upon information furnished by the Depositary with respect to its members, participants and any beneficial owners.  The Trustee and the Agents shall be entitled to deal with the Depositary, and any nominee thereof, that is the Holder of any Global Note for all purposes of this Indenture relating to such Global Note (including the payment of principal, premium, if any, and interest and additional amounts, if any, and the giving of instructions or directions by or to the owner or holder of a beneficial ownership interest in such Global Note) as the sole Holder of such Global Note and shall have no obligations to the beneficial owners thereof.  Neither the Trustee nor any Agent shall have any responsibility or

 

15

 

liability for any acts or omissions of the Depositary with respect to such Global Note, for the records of any such Depositary, including records in respect of beneficial ownership interests in respect of any such Global Note, for any transactions between the Depositary and any Depositary participant or between or among the Depositary, any such Depositary participant and/or any holder or owner of a beneficial interest in such Global Note, or for any transfers of beneficial interests in any such Global Note.

 

Notwithstanding the foregoing, with respect to any Global Note, nothing herein shall prevent the Company, the Trustee, or any Agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by any Depositary (or its nominee), as a Holder, with respect to such Global Note or shall impair, as between such Depositary and owners of beneficial interests in such Global Note, the operation of customary practices governing the exercise of the rights of such Depositary (or its nominee) as Holder of such Global Note.

 

Section 2.15                                                CUSIP Number.  The Company in issuing the Notes may use “CUSIP,” “ISIN” or other similar numbers (if then generally in use), and, if so, the Trustee shall use CUSIP, ISIN or other similar numbers in notices as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Notes or as contained in any notice and that reliance may be placed only on the other identification numbers printed on the Notes, and any such notice shall not be affected by any defect in or the omission of such numbers.  The Company shall promptly notify the Trustee in writing of any change in the CUSIP, ISIN or other similar numbers.

 

ARTICLE III

 

REDEMPTION AND PREPAYMENT

 

Section 3.01                                                Notice to Trustee.  The Company may, with respect to any Series of Notes, reserve the right to redeem and pay the Series of Notes or may covenant to redeem and pay the Series of Notes or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Notes.  If a Series of Notes is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Notes pursuant to the terms of such Notes, it shall notify the Trustee in writing of the redemption date and the principal amount of Series of Notes to be redeemed.  The Company shall give the notice at least 10 days prior to the mailing or sending of notice of redemption to the Holders of the Notes to be redeemed (unless a shorter period shall be satisfactory to the Trustee).

 

Section 3.02                                                Selection of Notes to Be Redeemed.  If less than all of the Notes of a Series are to be redeemed or purchased in an offer to purchase at any time, the Trustee (subject to the applicable procedures of the Depositary) shall select the Notes of a Series to be redeemed or purchased among the Holders of the Notes (a) in compliance with the requirements of the principal national securities exchange, if any, on which the Notes are listed or, (b) if the Notes are not so listed, on a pro rata basis, by lot or in accordance with any other method the Trustee deems fair and appropriate and, in the case of Global Notes, the Depositary will then select

 

16

 

Depositary participants holding the beneficial interests in the Notes to be redeemed in accordance with the Applicable Procedures of the Depositary.

 

The Trustee shall promptly notify the Company in writing of the Notes selected for redemption and, in the case of any Note selected for partial redemption, the principal amount thereof to be redeemed.  Notes of a Series and portions of them selected shall be in amounts of $2,000 or whole multiples of $1,000, or with respect to Notes of any Series issuable in other denominations pursuant to Section 2.02(j), the minimum principal denomination for each Series and integral multiples thereof.  Except as provided in the preceding sentence, provisions of this Indenture that apply to Notes of a Series called for redemption or repurchase also apply to portions of Notes of a Series called for redemption or repurchase.

 

Section 3.03                                                Notice of Redemption.  Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, at least 10 days but not more than 60 days before a redemption date, the Company shall deliver or cause to be delivered, by first class mail, or, in the case of the Depositary with respect to any Global Note, sent electronically, a notice of redemption to each Holder whose Notes are to be redeemed at its registered address.

 

The notice shall identify the Notes of the Series to be redeemed and shall state:

 

(1)                                 the redemption date;

 

(2)                                 the redemption price (or manner of calculation if not then known);

 

(3)                                 the name and address of the Paying Agent;

 

(4)                                 that Notes of the Series called for redemption must be surrendered to the Paying Agent to collect the redemption price;

 

(5)                                 that interest on Notes of the Series called for redemption ceases to accrue on and after the redemption date;

 

(6)                                 the CUSIP number, if any, provided that no representation is made as to the correctness or accuracy of the CUSIP number, if any, listed in such notice or printed on the Notes;

 

(7)                                 the conditions precedent, if any, to the redemption; and

 

(8)                                 any other information as may be required by the terms of the particular Series of the Notes or the Notes of a Series being redeemed.

 

At the Company’s request, and upon receipt of an Officer’s Certificate complying with Section 11.04 hereof at least 15 days prior to the date notice is to be given (unless a shorter period shall be satisfactory to the Trustee), together with the notice to be given setting forth the information to be stated therein as provided in the preceding paragraph, the Trustee shall give the notice of redemption in the Company’s name and at its expense.

 

17

 

Section 3.04                                                Effect of Notice of Redemption.  Once notice of redemption is sent in accordance with Section 3.03 hereof, Notes called for redemption become irrevocably due and payable on the redemption date at the redemption price.  Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, a notice of redemption may not be conditional.

 

Section 3.05                                                Deposit of Redemption Price.  At least one Business Day prior to the redemption date, the Company shall deposit with the Trustee or with the Paying Agent money sufficient to pay the redemption price of and accrued interest on all Notes to be redeemed on that date.  The Trustee or the Paying Agent shall promptly return to the Company any money deposited with the Trustee or the Paying Agent by the Company in excess of the amounts necessary to pay the redemption price of, and accrued interest on, all Notes to be redeemed.

 

If the Company complies with the provisions of the preceding paragraph, on and after the redemption date, interest shall cease to accrue on the Notes or the portions of Notes called for redemption.  If any Note called for redemption shall not be so paid upon surrender for redemption because of the failure of the Company to comply with the preceding paragraph, interest shall be paid on the unpaid principal, from the redemption date until such principal is paid, and to the extent lawful on any interest not paid on such unpaid principal, in each case at the rate provided in the Notes and in Section 4.01 hereof.

 

Section 3.06                                                Notes Redeemed in Part.  Upon surrender of a Note that is redeemed in part, the Company shall issue and, upon the Company’s written request, the Trustee shall authenticate for the Holder, or transfer by book-entry at the expense of the Company, a new Note equal in principal amount to the unredeemed portion of the Note surrendered.

 

No Notes of $2,000 or less can be redeemed in part (or with respect to Notes of any Series issuable in other denominations pursuant to Section 2.02(j), the minimum denomination for each Series and integral multiples thereof).

 

ARTICLE IV

 

COVENANTS

 

Section 4.01                                                Payment of Principal and Interest.  The Company covenants and agrees for the benefit of the Holders of each Series of Notes that it will pay or cause to be paid the principal of, premium, if any, and interest on such Series of Notes on the dates and in the manner provided in such Notes.  Principal, premium, if any, and interest on any Series of Notes will be considered paid on the date due if the Paying Agent, if other than the Company or a Subsidiary thereof, holds as of 10:00 a.m. Eastern Time on the due date money deposited by the Company in immediately available funds and designated for and sufficient to pay all principal, premium, if any, and interest then due.

 

Section 4.02                                                Maintenance of Office or Agency.  The Company covenants and agrees for the benefit of the Holders of each Series of Notes that it will maintain an office or agency (which may be an office of the Trustee for such Notes or an affiliate of the Trustee, Registrar for such Notes or co-registrar) where Notes may be surrendered for registration of transfer or for

 

18

 

exchange and where notices and demands to or upon the Company in respect of such Notes and this Indenture may be served.  The Company will give prompt written notice to the Trustee for such Notes of the location, and any change in the location, of such office or agency.  If at any time the Company fails to maintain any such required office or agency or fails to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee.

 

With respect to each Series of Notes, the Company hereby designates the Corporate Trust Office of the Trustee as one such office or agency of the Company in accordance with Section 2.04.

 

Section 4.03                                                Reports.  The Company will at all times comply with TIA § 314(a).  Delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee’s receipt of such shall not constitute actual or constructive knowledge or notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer’s Certificates).

 

Section 4.04                                                Compliance Certificate.  The Company and each guarantor of any Series of Notes (to the extent that such guarantor is so required under the TIA) shall deliver to the Trustee with respect to such Series, within 120 days after the end of each fiscal year, an Officer’s Certificate signed by the principal executive officer, the principal financial officer or the principal accounting officer, stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made under the supervision of the signing Officer with a view to determining whether the Company has kept, observed, performed and fulfilled its obligations under this Indenture, and further stating, as to the Officer signing such certificate, that to the best of his or her knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture and is not in default in the performance or observance of any of the terms, provisions and conditions of this Indenture (or, if a Default or Event of Default shall have occurred, describing all such Defaults or Events of Default of which he or she may have knowledge and what action the Company is taking or proposes to take with respect thereto) and that to the best of his or her knowledge no event has occurred and remains in existence by reason of which payments on account of the principal of or interest, if any, on the Notes is prohibited or if such event has occurred, a description of the event and what action the Company is taking or proposes to take with respect thereto.

 

Section 4.05                                                Taxes.  The Company will pay, and will cause each of its Subsidiaries to pay, prior to delinquency, all material taxes, assessments, and governmental levies except such as are contested in good faith and by appropriate proceedings or where the failure to effect such payment is not adverse in any material respect to the Holders of the Notes.

 

Section 4.06                                                Stay, Extension and Usury Laws.  The Company covenants (to the extent that it may lawfully do so) that it will not, and each guarantor of such Notes will not, at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, that may affect the covenants or the performance of this Indenture; and the Company and each of such guarantors (to the extent that it may lawfully do so), as applicable, hereby expressly waives

 

19

 

all benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee for such Notes, but will suffer and permit the execution of every such power as though no such law has been enacted.

 

Section 4.07                                                Corporate Existence.  Subject to Article V hereof, the Company shall do or cause to be done all things necessary to preserve and keep in full force and effect:

 

(a)                                 its corporate existence, and the corporate, partnership or other existence of each of its Subsidiaries, in accordance with the respective organizational documents (as the same may be amended from time to time) of the Company or any such Subsidiary; and

 

(b)                                 the rights (charter and statutory), licenses and franchises of the Company and its Subsidiaries; provided, however, that the Company shall not be required to preserve any such right, license or franchise, or the corporate, partnership or other existence of any of its Subsidiaries, if an Officer shall determine that the preservation thereof is no longer desirable in the conduct of the business of the Company and its Subsidiaries, taken as a whole, and that the loss thereof is not adverse in any material respect to the Holders of the Notes.

 

ARTICLE V

 

SUCCESSORS

 

Section 5.01                                                Merger, Consolidation, or Sale of Assets.  The Company shall not, directly or indirectly:

 

(a)                                 merge or consolidate with or into another Person or Persons; or

 

(b)                                 sell, convey, transfer, lease or otherwise dispose of all or substantially all of the properties or assets of the Company and its Subsidiaries taken as a whole, in one or more related transactions, to another Person or Persons, unless:

 

(1)                                 either:

 

(A)                               the transaction is a merger or consolidation and the Company is the surviving corporation; or

 

(B)                               the Person formed by or surviving any such consolidation or merger (if other than the Company) or to which such sale, conveyance, transfer, lease or other disposition has been made is a corporation, limited liability company, partnership, trust or other entity organized and existing under the laws of the United States, any state of the United States or the District of Columbia and expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to a supplemental indenture in form reasonably satisfactory to the Trustee;

 

(2)                                 immediately after giving effect to such transaction and treating the Company’s obligations in connection with or as a result of such transaction as having been

 

20

 

incurred as of the time of such transaction, no Default or Event of Default shall have occurred and be continuing; and

 

(3)                                 the Company or the surviving entity shall have delivered to the Trustee (a) an Officer’s Certificate stating that the conditions in (1) and (2) above have been satisfied and any other conditions precedent in this Indenture relating to such transaction have been complied with and (b) an Opinion of Counsel stating that the conditions in (1) above have been satisfied and any other conditions precedent in this Indenture relating to such transaction have been complied with.

 

Section 5.02                                                Successor Corporation Substituted.  Upon any merger or consolidation, or any sale, conveyance, transfer, lease or other disposition of all or substantially all of the properties or assets of the Company and its Subsidiaries in a transaction that is subject to, and that complies with the provisions of, Section 5.01 hereof, the successor Person into which the Company is merged or formed by such consolidation or to which such sale, conveyance, transfer, lease or other disposition is made shall succeed to, and be substituted for (so that from and after the date of such merger, consolidation, sale, conveyance, transfer, lease or other disposition, the provisions of this Indenture referring to the “Company” shall refer instead to the successor Person and not to the Company), and may exercise every right and power of the Company under this Indenture with the same effect as if such successor Person had been named as the Company herein; provided, however, that the predecessor Company shall not be relieved from the obligation to pay the principal of and interest on any Series of Notes except in the case of a sale of all of the assets of the Company and its Subsidiaries in a transaction that is subject to, and that complies with the provisions of, Section 5.01 hereof.

 

ARTICLE VI

 

DEFAULTS AND REMEDIES

 

Section 6.01                                                Events of Default.  “Event of Default,” wherever used herein with respect to Notes of any Series, means any one of the following events, unless in the establishing Board Resolution, supplemental indenture or Officer’s Certificate, it is provided that such Series shall not have the benefit of said Event of Default:

 

(a)                                 default in the payment of any interest on any Note of that Series when it becomes due and payable, and continuance of such default for a period of 30 days; or

 

(b)                                 default in payment when due of the principal of, or premium, if any, on any Note of that Series when the same becomes due and payable at maturity, upon acceleration, declaration or redemptions or otherwise; or

 

(c)                                  default in the performance or breach of any covenant or warranty of the Company in this Indenture or in any Board Resolution, supplemental indenture or Officer’s Certificate with respect to such Series (other than a covenant or warranty that has been included in this Indenture or a Board Resolution, supplemental indenture or Officer’s Certificate solely for the benefit of Series of Notes other than that Series), which default continues uncured for a period of 90 days after (i) the Company receives written notice from the Trustee for such Notes

 

21

 

or (ii) the Company and the Trustee receive written notice from Holders of not less than 25% in aggregate principal amount of Notes of that Series outstanding; or

 

(d)                                 the Company:

 

(1)                                 commences a voluntary case under applicable bankruptcy, insolvency or other similar law,

 

(2)                                 consents to the entry of an order for relief against it in an involuntary bankruptcy case,

 

(3)                                 applies for or consents to the appointment of any custodian, receiver, trustee, sequestrator, conservator, liquidator, rehabilitator or similar officer of it or for all or substantially all of its property and assets,

 

(4)                                 makes a general assignment for the benefit of its creditors, or

 

(5)                                 generally is unable to pay its debts as they become due;

 

(e)                                  an involuntary case or other proceeding is commenced against the Company with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding remains undismissed and unstayed for a period of 60 consecutive days; or an order for relief is entered against the Company under the federal bankruptcy laws as now or hereafter in effect; or

 

(f)                                   any other Event of Default provided with respect to Notes of that Series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officer’s Certificate, in accordance with Section 2.02.

 

Section 6.02                                                Acceleration.  If an Event of Default with respect to Notes of any Series at the time outstanding occurs and is continuing (other than an Event of Default referred to in Section 6.01(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in aggregate principal amount of the outstanding Notes of that Series may declare the principal amount of and accrued and unpaid interest, if any, on all of the Notes of that Series to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and payable.  If an Event of Default specified in Section 6.01(d) or (e) shall occur, the principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Notes shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.

 

At any time after such a declaration of acceleration with respect to any Series has been made, the Holders of a majority in principal amount of the outstanding Notes of that Series, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if (i) the rescission and annulment would not conflict with any judgment or decree

 

22

 

already rendered, (ii) if all existing Events of Default with respect to that Series (except nonpayment of principal, interest or premium that has become due solely because of the acceleration) have been cured or waived and all sums paid or advanced by the Trustee hereunder and the reasonable compensation expenses and disbursements of the Trustee and its agents and counsel have been paid and (iii) if the Company has paid or deposited with the Trustee a sum sufficient to pay (a) any overdue interest on the Notes of such Series, (b) the principal amount of such Series of Notes (except the principal, interest or premium that has become due solely because of the acceleration) and (c) to the extent lawful and applicable, interest on overdue installments of interest at the rate specified in the Notes of such Series.

 

No such rescission shall affect any subsequent Event of Default or impair any right consequent thereon.

 

Section 6.03                                                Other Remedies.  If an Event of Default with respect to Notes of any Series at the time outstanding occurs and is continuing, the Trustee may pursue any available remedy to collect the payment of principal, premium, if any, and interest on such Notes or to enforce the performance of any provision of such Notes or this Indenture.

 

The Trustee may maintain a proceeding even if it does not possess any of the Notes or does not produce any of them in the proceeding.  A delay or omission by the Trustee or any Holder of a Note in exercising any right or remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default.  All remedies are cumulative to the extent permitted by law.

 

Section 6.04                                                Waiver of Past Defaults.  Prior to the acceleration of the maturity of the Notes of any Series as provided in Section 6.02, the Holders of a majority in aggregate principal amount of the Notes of any Series then outstanding by notice to the Trustee may on behalf of the Holders of all of the Notes of such Series waive any existing Default or Event of Default with respect to such Series and its consequences under this Indenture except (i) a continuing Default or Event of Default in the payment of premium or interest on, or the principal of, the Notes of such Series (including in connection with an offer to purchase) or (ii) a Default or Event of Default in respect of a provision that under Section 9.02 cannot be amended without the consent of each Holder affected thereby.  Upon any such waiver, such Default or Event of Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon.

 

Section 6.05                                                Control by Majority.  Holders of a majority in aggregate principal amount of the then outstanding Notes of any Series may in writing direct the time, method and place of conducting any proceeding for exercising any remedy available to the Trustee or exercising any trust or power conferred on it, subject to Section 7.02(f).  However, the Trustee may refuse to follow any direction that conflicts with law or this Indenture that the Trustee determines may be unduly prejudicial to the rights of other Holders of Notes of such Series (it being understood that the Trustee does not have an affirmative duty to ascertain whether any such directions are unduly prejudicial to such Holders) or that may involve the Trustee in personal liability.  The Trustee may take any other action deemed proper by the Trustee that is not inconsistent with such direction.

 

23

 

Section 6.06                                                Limitation on Suits.  A Holder of any Series of Notes may pursue a remedy with respect to this Indenture or the Notes only if:

 

(a)                                 the Holder of a Note gives to the Trustee written notice of a continuing Event of Default;

 

(b)                                 the Holders of at least 25% in aggregate principal amount of the then outstanding Notes of such Series make a written request to the Trustee to pursue the remedy;

 

(c)                                  such Holder of a Note or Holders of Notes offer and, if requested, provide to the Trustee security or indemnity satisfactory to the Trustee against any loss, liability or expense;

 

(d)                                 the Trustee does not comply with the request within 60 days after receipt of the request and the offer and, if requested, the provision of security or indemnity; and

 

(e)                                  during such 60-day period the Holders of a majority in aggregate principal amount of the then outstanding Notes of such Series do not give the Trustee a direction inconsistent with the request.

 

A Holder of any Series of Notes may not use this Indenture to prejudice the rights of another Holder of Notes or to obtain a preference or priority over another Holder of Notes.

 

Section 6.07                                                Rights of Holders of Notes to Receive Payment.  Notwithstanding any other provision of this Indenture, the right of any Holder of a Note to receive payment of principal, premium, if any, and interest on the Note, on or after the respective due dates expressed in the Note (including in connection with an offer to purchase), or to bring suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder.

 

Section 6.08                                                Collection Suit by Trustee.  If an Event of Default specified in Section 6.01 (a) or (b) hereof occurs and is continuing, the Trustee is authorized to recover judgment in its own name and as trustee of an express trust against the Company for the whole amount of principal of, premium, if any, and interest remaining unpaid on, the Notes and interest on overdue principal and, to the extent lawful, interest and such further amount as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel.

 

Section 6.09                                                Trustee May File Proofs of Claim.  The Trustee for each Series of Notes is authorized to file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and the Holders of the Notes of such Series allowed in any judicial proceedings relative to the Company (or any other obligor upon the Notes of such Series), its creditors or its property and shall be entitled and empowered to collect, receive and distribute any money or other property payable or deliverable on any such claims and any custodian in any such judicial proceeding is hereby authorized by each Holder of such Series to make such payments to the Trustee, and in the event that the Trustee shall consent to the making of such payments directly

 

24

 

to the Holders of such Series, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.07 hereof.  To the extent that the payment of any such compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.07 hereof out of the estate in any such proceeding, shall be denied for any reason, payment of the same shall be secured by a Lien on, and shall be paid out of, any and all distributions, dividends, money, securities and other properties that the Holders of such Series may be entitled to receive in such proceeding whether in liquidation or under any plan of reorganization or arrangement or otherwise.  Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Notes or the rights of any Holder, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.

 

Section 6.10                                                Priorities.  If the Trustee collects any money or property with respect to a Series of Notes pursuant to this Article VI, or, after an Event of Default, any money or other property distributable in respect of the Company’s obligations under this Indenture, it shall pay out the money or property in the following order:

 

First:  to the Trustee (including any predecessor trustee), its agents and attorneys for amounts due under Section 7.07 hereof applicable to the Notes of such Series, including payment of all compensation, expenses and liabilities incurred, and all advances made, by the Trustee and the costs and expenses of collection;

 

Second:  to Holders of Notes of such Series for amounts due and unpaid on the Notes for principal, premium, if any, and interest, ratably, without preference or priority of any kind, according to the amounts due and payable on the Notes for principal, premium, if any, and interest, respectively; and

 

Third:  to the Company or to such party as a court of competent jurisdiction shall direct.

 

The Trustee may fix a record date and payment date for any payment to Holders pursuant to this Section 6.10.

 

Section 6.11                                                Undertaking for Costs.  In any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken or omitted by it as a Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in the suit, having due regard to the merits and good faith of the claims or defenses made by the party litigant.  This Section does not apply to a suit by the Trustee, a suit by a Holder of a Note pursuant to Section 6.07 hereof, or a suit by Holders or group of Holders of more than 10% in principal amount of the then outstanding Notes of any Series.

 

Section 6.12                                                Restoration of Rights and Remedies.  If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined

 

25

 

adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee, and the Holders will be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders will continue as though no such proceeding had been instituted.

 

Section 6.13                                                Waiver of Stay, Extension or Usury Laws.  The Company covenants, to the extent that it may lawfully do so, that it shall not at any time insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay or extension law or any usury law or other law that would prohibit or forgive the Company from paying all or any portion of the principal of, premium, if any, or interest (including additional interest, if any) on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the performance of the Indenture.  The Company hereby expressly waives, to the extent that it may lawfully do so, all benefit or advantage of any such law and covenants that it shall not hinder, delay or impede the execution of any power herein granted to the Trustee, but shall suffer and permit the execution of every such power as if no such law had been enacted.

 

ARTICLE VII

 

TRUSTEE

 

Section 7.01                                                Duties of Trustee.

 

(a)                                 If an Event of Default has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in its exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs.

 

(b)                                 Except during the continuance of an Event of Default,

 

(1)         the duties of the Trustee will be determined solely by the express provisions of this Indenture and the Trustee need perform only those duties that are specifically set forth in this Indenture and no others, and no implied covenants or obligations shall be read into this Indenture against the Trustee; and

 

(2)         in the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture.  However, the Trustee will examine the certificates and opinions to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical calculations or other facts, statements, opinions or conclusions stated thereon).

 

(c)                                  The Trustee may not be relieved from liabilities for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that:

 

26

 

(1)                                 this paragraph does not limit the effect of paragraph (b) of this Section 7.01;

 

(2)                                 the Trustee will not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts;

 

(3)                                 the Trustee will not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction received by it pursuant to Section 6.05 hereof; and

 

(4)                                 no provision of this Indenture will require the Trustee to expend or risk its own funds or incur any liability.  The Trustee will be under no obligation to exercise any of its rights and powers under this Indenture at the request of any Holders, unless such Holder has offered to the Trustee security and/or indemnity satisfactory to the Trustee against any loss, liability or expense.

 

(d)                                 Whether or not therein expressly so provided, every provision of this Indenture that in any way relates to the Trustee is subject to this Section 7.01.

 

(e)                                  The Trustee will not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company.  Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law.  The Trustee shall not be required to give any bond or surety in respect of the performance of its powers or duties hereunder.  The permissive rights or powers of the Trustee to do things enumerated in this Indenture shall not be construed as a duty of the Trustee.

 

Section 7.02                                                Rights of Trustee.  Subject to the provisions of Section 7.01:

 

(a)                                 The Trustee may conclusively rely and shall be fully protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document (whether in its original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper Person or Persons.  The Trustee need not investigate any fact or matter stated in the document.

 

(b)                                 Before the Trustee acts or refrains from acting or as specifically called for in this Indenture, it may require an Officer’s Certificate or an Opinion of Counsel or both.  The Trustee will not be liable for any action it takes or omits to take in good faith in reliance on such Officer’s Certificate or Opinion of Counsel.  The Trustee may consult with counsel and the advice of such counsel or any Opinion of Counsel will be full and complete authorization and protection from liability in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon.

 

(c)                                  The Trustee may act through its attorneys and agents and will not be responsible for the misconduct or negligence of any attorney or agent appointed with due care.

 

27

 

(d)                                 The Trustee will not be liable for any action it takes or omits to take in good faith that it believes to be authorized or within the rights or powers conferred upon it by this Indenture.

 

(e)                                  Unless otherwise specifically provided in this Indenture, any demand, request, direction or notice from the Company will be sufficient if signed by an Officer of the Company.  Any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution.

 

(f)                                   The Trustee will be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders unless such Holders have offered to the Trustee indemnity or security satisfactory to the Trustee against the losses, liabilities and expenses that might be incurred by it in compliance with such request or direction.

 

(g)                                  In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, or other unavailability of the Federal Reserve Bank wire or facsimile or other wire or communication facility; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.

 

(h)                                 In no event shall the Trustee be responsible or liable for special, indirect, punitive, or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action.

 

(i)                                     The rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be compensated, reimbursed, and indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and each agent, custodian and other Person employed to act hereunder.

 

(j)                                    The Trustee shall not be deemed to have notice or be charged with knowledge of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of a Default or Event of Default from the Company or by the Holders of at least 25% in aggregate principal amount of the then outstanding Notes of such Series is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the Notes and this Indenture.

 

(k)                                 The Trustee may request that the Company deliver a certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture.

 

(l)                                     The Trustee will not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice,

 

28

 

request, direction, consent, order, bond, debenture, note, other evidence of indebtedness, or other paper or document, or inquire as to the performance by the Company or any guarantor of any of their covenants in this Indenture, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it will be entitled to examine the books, records, and premises of the Company or any such guarantor, personally or by agent or attorney at the sole cost of the Company and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation

 

(m)                             In order to comply with applicable tax laws, rules and regulations (inclusive of directives, guidelines and interpretations promulgated by competent authorities) in effect from time to time (“Applicable Law”) related to this Indenture, the Company agrees (i) to provide to the Trustee sufficient information about holders or other applicable parties and/or transactions (including any modification to the terms of such transactions) as the Trustee may reasonably request so the Trustee can determine whether it has tax related obligations under Applicable Law, but only to the extent that the Company possesses such information, (ii) that the Trustee shall be entitled to make any withholding or deduction from payments under this Indenture to the extent necessary to comply with Applicable Law for which the Trustee shall not have any liability, and (iii) to indemnify and hold harmless the Trustee for any losses it may suffer due to the actions it takes in good faith to comply with such Applicable Law.  The terms of this section shall survive the termination of this Indenture.

 

Section 7.03                                                Individual Rights of Trustee.  The Trustee in its individual or any other capacity may become the owner or pledgee of Notes and may otherwise deal with the Company or any Affiliate of the Company with the same rights it would have if it were not Trustee.  However, in the event that the Trustee acquires any conflicting interest as defined in the TIA it must eliminate such conflict within 90 days, apply to the SEC for permission to continue as Trustee (if this Indenture has been qualified under the TIA) or resign.  Any Agent may do the same with like rights and duties.  The Trustee is also subject to Sections 7.10 and 7.11 hereof.

 

Section 7.04                                                Trustee’s Disclaimer.  The Trustee will not be responsible for and makes no representation as to the validity, sufficiency or adequacy of this Indenture or the Notes, it shall not be accountable for the Company’s use of the proceeds from the Notes or any money paid to the Company or upon the Company’s direction under any provision of this Indenture, it will not be responsible for the use or application of any money received by any Paying Agent other than the Trustee, and it will not be responsible for any statement or recital herein or any statement in the Notes or any other document in connection with the sale of the Notes or pursuant to this Indenture other than its certificate of authentication.  Under no circumstances shall the Trustee be liable in its individual capacity for the obligations evidenced by any Notes.  The Trustee shall not be responsible to make any calculation with respect to any matter under this Indenture.  The Trustee shall have no duty to monitor or investigate the Company’s compliance with or the breach of, or cause to be performed or observed, any representation, warranty, or covenant, or agreement of any Person, other than the Trustee, made in this Indenture.

 

Section 7.05                                                Notice of Defaults.  If a Default or Event of Default occurs and is continuing and if it is known to the Trustee, the Trustee will mail to Holders of Notes a notice of the Default or Event of Default within 90 days after it occurs.  Except in the case of a Default or

 

29

 

Event of Default in payment of principal of, premium, if any, or interest on, any Note, the Trustee may withhold the notice from Holders of the Notes if and so long as a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of the Holders of the Notes.

 

Section 7.06                                                Reports by Trustee to Holders of the Notes.

 

(a)                                 Within 60 days after each April 15 beginning with the April 15 following the date of this Indenture, and for so long as Notes remain outstanding, the Trustee will mail to the Holders of the Notes a brief report dated as of such reporting date that complies with TIA § 313(a) (but if no event described in TIA § 313(a) has occurred within the twelve months preceding the reporting date, no report need be transmitted).  The Trustee also will comply with TIA § 313(b)(2).  The Trustee will also transmit by mail all reports as required by TIA § 313(c).

 

(b)                                 A copy of each report at the time of its mailing to the Holders of Notes will be mailed by the Trustee to the Company and filed by the Trustee with the SEC and each stock exchange on which the Notes are listed in accordance with TIA § 313(d).  The Company will promptly notify the Trustee when the Notes are listed on any stock exchange or delisted therefrom.

 

Section 7.07                                                Compensation and Indemnity.

 

(a)                                 The Company will pay to the Trustee from time to time such compensation for its acceptance of this Indenture and services hereunder as the Trustee and the Company may agree from time to time in writing.  The Trustee’s compensation will not be limited by any law on compensation of a trustee of an express trust.  The Company will reimburse the Trustee promptly upon request for all reasonable disbursements, advances and expenses incurred or made by it in addition to the compensation for its services.  Such expenses will include the reasonable compensation, disbursements and expenses of the Trustee’s agents and counsel.

 

(b)                                 The Company will indemnify the Trustee (including any predecessor Trustee), its officers, directors, employees, representatives and agents from and against any and all losses, liabilities, damages, claims or expenses, including fees and expenses of counsel incurred by it arising out of or in connection with this Indenture, the Notes, the acceptance or administration of the trusts or its duties under this Indenture, including the costs and expenses of enforcing this Indenture against the Company (including this Section 7.07) and defending itself against any claim (whether asserted by the Company, any Holder or any other Person) or liability in connection with the exercise or performance of any of its powers or duties hereunder, except to the extent any such loss, liability, damage, claim or expense may be attributable to its negligence or willful misconduct.  The Trustee will notify the Company promptly of any claim for which it may seek indemnity.  Failure by the Trustee to so notify the Company will not relieve the Company of its obligations hereunder.  The Company will defend the claim and the Trustee will cooperate in the defense.  The Trustee may have separate counsel and the Company will pay the reasonable fees and expenses of such counsel.  The Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld.

 

30

 

(c)                                  The obligations of the Company under this Section 7.07 will survive the resignation or removal of the Trustee, the termination for any reason of this Indenture, and the satisfaction and discharge of this Indenture and the Notes.

 

(d)                                 To secure the Company’s payment obligations in this Section 7.07, the Trustee will have a Lien prior to the Notes on all money and property held or collected by the Trustee.  Such Lien will survive the resignation or removal of the Trustee and the satisfaction and discharge of this Indenture.

 

(e)                                  When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.01(d) or (e) hereof occurs, the expenses and the compensation for the services (including the fees and expenses of its agents and counsel) are intended to constitute expenses of administration under any Bankruptcy Law.

 

(f)                                   The Trustee will comply with the provisions of TIA § 313(b)(2) to the extent applicable.

 

(g)                                  “Trustee” for the purposes of this Section 7.07 shall include any predecessor Trustee and the Trustee in each of its capacities hereunder and each agent, custodian and other Person employed to act hereunder; provided, however, that the negligence or willful misconduct of any Trustee hereunder shall not affect the rights of any other Trustee hereunder.

 

Section 7.08                                                Replacement of Trustee.

 

(a)                                 A resignation or removal of the Trustee and appointment of a successor Trustee will become effective only upon the successor Trustee’s acceptance of appointment as provided in this Section 7.08.

 

(b)                                 The Trustee may resign in writing at any time and be discharged from the trust hereby created with respect to one or more Series of Notes by so notifying the Company with 30 days prior notice.

 

(c)                                  The Holders of a majority in aggregate principal amount of the then outstanding Notes of such Series may remove the Trustee by so notifying the Trustee and the Company with 30 days prior notice in writing.

 

(d)                                 The Company may remove the Trustee with respect to one or more Series of Notes with 30 days prior written notice if:

 

(1)                                 the Trustee fails to comply with Section 7.10 hereof;

 

(2)                                 the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;

 

(3)                                 a custodian or public officer takes charge of the Trustee or its property; or

 

(4)                                 the Trustee becomes incapable of acting.

 

31

 

(e)                                  If the Trustee has been removed by the Holders, Holders of a majority in aggregate principal amount outstanding of such Series of Notes (voting as a single class) may appoint a successor Trustee with the consent of the Company.  Otherwise, if the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company will promptly appoint a successor Trustee.  If a successor Trustee does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company, or the Holders of at least 10% in aggregate principal amount of the then outstanding Notes of such Series may petition any court of competent jurisdiction, at the expense of the Company, for the appointment of a successor Trustee.

 

(f)                                   If the Trustee, after written request by any Holder who has been a Holder for at least six months, fails to comply with Section 7.10 hereof, such Holder may petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee.

 

(g)                                  A successor Trustee will deliver a written acceptance of its appointment to the retiring Trustee and to the Company.  Thereupon, the resignation or removal of the retiring Trustee will become effective, and the successor Trustee will have all the rights, powers and duties of the Trustee under this Indenture.  The successor Trustee will mail a notice of its succession to Holders.  The retiring Trustee will promptly transfer all properly held by it as Trustee to the successor Trustee; provided all sums owing to the Trustee hereunder have been paid and subject to the Lien provided for in Section 7.07 hereof.  Notwithstanding replacement of the Trustee pursuant to this Section 7.08, the Company’s obligations under Section 7.07 hereof will continue for the benefit of the retiring Trustee.

 

Section 7.09                                                Successor Trustee by Merger, etc.  If the Trustee consolidates, merges or converts into, or transfers all or substantially all of its corporate trust business to, another Person, the successor Person without any further act will be the successor Trustee.

 

Section 7.10                                                Eligibility; Disqualification.  There will at all times be a Trustee hereunder that is a Person organized and doing business under the laws of the United States of America or of any state thereof that is authorized under such laws to exercise corporate trustee power, that is subject to supervision or examination by federal or state authorities and that has a combined capital and surplus of at least $100.0 million as set forth in its most recent published annual report of condition.

 

This Indenture will always have a Trustee who satisfies the requirements of TIA § 310(a)(l), (2) and (5).  The Trustee is subject to TIA § 310(b).  There shall be excluded from the operation of TIA § 310(b)(1) any series of Notes under this Indenture if the requirements for such exclusion set forth in TIA § 310(b)(1) are met.

 

Section 7.11                                                Preferential Collection of Claims Against Company.  The Trustee is subject to TIA § 311(a), excluding any creditor relationship listed in TIA § 311(b).  A Trustee who has resigned or been removed shall be subject to TIA § 311(a) to the extent indicated therein.

 

32

 

ARTICLE VIII

 

LEGAL DEFEASANCE AND COVENANT DEFEASANCE

 

Section 8.01                                                Option to Effect Legal Defeasance or Covenant Defeasance.  The Company may at any time, at the option of its Board of Directors evidenced by a resolution set forth in an Officer’s Certificate, elect to have either Section 8.02 or 8.03 hereof be applied to all outstanding Notes upon compliance with the conditions set forth below in this Article VIII.

 

Section 8.02                                                Legal Defeasance and Discharge.  Upon the Company’s exercise under Section 8.01 hereof of the option applicable to this Section 8.02, the Company will, subject to the satisfaction of the conditions set forth in Section 8.04 hereof, be deemed to have been discharged from its obligations with respect to all outstanding Notes of such Series on the date the conditions set forth below are satisfied (hereinafter, “Legal Defeasance”).  For this purpose, Legal Defeasance means that the Company will be deemed to have paid and discharged the entire Indebtedness represented by the outstanding Notes of such Series, which will thereafter be deemed to be “outstanding” only for the purposes of Section 8.05 hereof and the other Sections of this Indenture referred to in clauses (a) and (b) below, and to have satisfied all their other obligations under such Notes and this Indenture (and the Trustee, on written demand of and at the expense of the Company, shall execute proper instruments acknowledging the same), except for the following provisions which will survive until otherwise terminated or discharged hereunder:

 

(a)                                 the rights of Holders of outstanding Notes to receive payments in respect of the principal of, or interest or premium, if any, on, such Notes when such payments are due from the trust referred to in Section 8.04 hereof;

 

(b)                                 the Company’s obligations with respect to such Notes under Article II and Section 4.02 hereof;

 

(c)                                  the rights, powers, trusts, duties and immunities of the Trustee hereunder and the Company’s obligations in connection therewith; and

 

(d)                                 this Article VIII.

 

Subject to compliance with this Article VIII, the Company may exercise its option under this Section 8.02 notwithstanding the prior exercise of its option under Section 8.03 hereof.

 

Section 8.03                                                Covenant Defeasance.  Upon the Company’s exercise under Section 8.01 hereof of the option applicable to this Section 8.03, the Company and each of the guarantors, if any, will, subject to the satisfaction of the conditions set forth in Section 8.04 hereof, be released from their obligations under the covenants contained in Section 4.03 and any other covenants specified in the applicable Board Resolutions, supplemental indenture or Officer’s Certificate as being subject to covenant defeasance pursuant to this Section 8.03, each case, with respect to the outstanding Notes of the applicable Series on and after the date the conditions set forth in Section 8.04 are satisfied (hereinafter, “Covenant Defeasance”), and the Notes shall thereafter be deemed not “outstanding” for the purposes of any direction, waiver, consent or declaration or act of Holders (and the consequences of any thereof) in connection with

 

33

 

such covenants, but shall continue to be deemed “outstanding” for all other purposes hereunder (it being understood that such Notes shall not be deemed outstanding for accounting purposes).  For this purpose, Covenant Defeasance means that, with respect to the outstanding Notes of such Series, the Company may omit to comply with and shall have no liability in respect of any term, condition or limitation set forth in any such covenant, whether directly or indirectly, by reason of any reference elsewhere herein to any such covenant or by reason of any reference in any such covenant to any other provision herein or in any other document and such omission to comply shall not constitute a Default or an Event of Default under Section 6.01 hereof, but, except as specified above, the remainder of this Indenture and such Notes shall be unaffected thereby.  In addition, upon the Company’s exercise under Section 8.01 hereof of the option applicable to this Section 8.03 hereof, subject to the satisfaction of the conditions set forth in Section 8.04 hereof, the failure to comply with any such covenant shall not constitute an Event of Default pursuant to Section 6.01(c).

 

Section 8.04                                                Conditions to Legal or Covenant Defeasance.  In order to exercise either Legal Defeasance or Covenant Defeasance under either Section 8.02 or 8.03 hereof:

 

(a)                                 the Company must irrevocably deposit with the Trustee, in trust, for the benefit of the Holders, cash in U.S. dollars, non-callable Government Securities, or a combination thereof, in such amounts as will be sufficient, without consideration of any investment of interest, in the written opinion of a nationally recognized investment bank, appraisal firm, or firm of independent public accountants delivered to the Trustee, to pay and discharge the principal of, premium, if any, and interest on, the outstanding Notes on the stated date for payment thereof or on the applicable redemption date, as the case may be, and the Company must specify whether the Notes are being defeased to such stated date for payment or to a particular redemption date;

 

(b)                                 in the case of an election under Section 8.02 hereof, the Company must deliver to the Trustee an Opinion of Counsel confirming that:

 

(1)                                 the Company has received from, or there has been published by, the Internal Revenue Service a ruling; or

 

(2)                                 since the date of this Indenture, there has been a change in the applicable federal income tax law,

 

in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the beneficial owners of the outstanding Notes will not recognize income, gain or loss for federal income tax purposes as a result of such Legal Defeasance and will be subject to federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such Legal Defeasance had not occurred;

 

(c)                                  in the case of an election under Section 8.03 hereof, the Company must deliver to the Trustee an Opinion of Counsel confirming that the beneficial owners of the outstanding Notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such Covenant Defeasance and will be subject to U.S. federal income tax on the

 

34

 

same amounts, in the same manner and at the same times as would have been the case if such Covenant Defeasance had not occurred;

 

(d)                                 no Default or Event of Default shall have occurred and be continuing on the date of such deposit (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit) and the deposit will not result in a breach or violation of, or constitute a default under, any other instrument to which the Company is a party or by which the Company is bound;

 

(e)                                  such Legal Defeasance or Covenant Defeasance will not result in a breach or violation of, or constitute a default under, any material agreement or instrument (other than this Indenture) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound;

 

(f)                                   the Company must deliver to the Trustee an Officer’s Certificate stating that the deposit was not made by the Company with the intent of preferring the Holders of Notes over the other creditors of the Company with the intent of defeating, hindering, delaying or defrauding any creditors of the Company or others; and

 

(g)                                  the Company must deliver to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent relating to the Legal Defeasance or the Covenant Defeasance have been complied with.

 

Section 8.05                                                Deposited Money and Government Securities to be Held in Trust; Other Miscellaneous Provisions.  Subject to Section 8.06 hereof, all money and non-callable Government Securities (including the proceeds thereof) deposited with the Trustee (or other qualifying trustee, collectively for purposes of this Section 8.05, the “Trustee”) pursuant to Section 8.04 hereof in respect of the outstanding Notes of any Series will be held in trust and applied by the Trustee, in accordance with the provisions of such Notes and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as Paying Agent) as the Trustee may determine, to the Holders of such Notes of all sums due and to become due thereon in respect of principal, premium, if any, and interest, but such money need not be segregated from other funds except to the extent required by law.

 

The Company will pay and indemnify the Trustee against any tax, fee or other charge imposed on or assessed against the cash or non-callable Government Securities deposited pursuant to Section 8.04 hereof or the principal and interest received in respect thereof other than any such tax, fee or other charge which by law is for the account of the Holders of the outstanding Notes of the applicable Series.

 

Notwithstanding anything in this Article VIII to the contrary, the Trustee will deliver or pay to the Company from time to time upon the request of the Company any money or non-callable Government Securities held by it as provided in Section 8.04 hereof which, in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee (which may be the opinion delivered under Section 8.04(a) hereof), are in excess of the amount thereof that would then be required to be deposited to effect an equivalent Legal Defeasance or Covenant Defeasance.

 

35

 

Section 8.06                                                Repayment to Company.  Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal of, premium, if any, or interest on, any Series of Notes and remaining unclaimed for two years after such principal, premium, if any, or interest has become due and payable shall, subject to applicable abandoned property law, be paid to the Company on its request or (if then held by the Company) will be discharged from such trust; and the Holder of such Note will thereafter be permitted to look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money, and all liability of the Company as trustee thereof, will thereupon cease; provided, however, that the Trustee or such Paying Agent, before being required to make any such repayment, may at the expense of the Company cause to be published once, in The New York Times and The Wall Street Journal (national edition), notice that such money remains unclaimed and that, after a date specified therein, which will not be less than 30 days from the date of such notification or publication, any unclaimed balance of such money then remaining will be repaid to the Company.

 

Section 8.07                                                Reinstatement.  If the Trustee or Paying Agent is unable to apply any U.S. dollars or non-callable Government Securities in accordance with Section 8.02 or 8.03 hereof, as the case may be, by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, then the Company’s and any applicable guarantors’ obligations under this Indenture and the applicable Notes and the guarantees will be revived and reinstated as though no deposit had occurred pursuant to Section 8.02 or 8.03 hereof until such time as the Trustee or Paying Agent is permitted to apply all such money in accordance with Section 8.02 or 8.03 hereof, as the case may be; provided, however, that, if the Company makes any payment of principal of, premium, if any, or interest on, any Note following the reinstatement of its obligations, the Company will be subrogated to the rights of the Holders of such Notes to receive such payment from the money held by the Trustee or Paying Agent.

 

ARTICLE IX

 

AMENDMENT, SUPPLEMENT AND WAIVER

 

Section 9.01                                                Without Consent of Holders of Notes.  Notwithstanding Section 9.02 of this Indenture, the Company and the Trustee may amend or supplement this Indenture or the Notes of one or more Series without the consent of any Holder of a Note:

 

(a)                                 to cure any ambiguity or to correct or supplement any provision contained herein or in any supplemental indenture that may be defective or inconsistent with any other provision contained herein or in any supplemental indenture, or to conform the provisions of this Indenture to the description of the Notes contained in the prospectus or other offering document pursuant to which the Notes of one or more Series were sold, as evidenced by an Officer’s Certificate stating that such text constitutes an unintended conflict with the description of the corresponding provision in the offering document;

 

(b)                                 to provide for uncertificated Notes in addition to or in place of certificated Notes;

 

36

 

(c)                                  to provide for the assumption of the Company’s obligations to the Holders of the Notes by a successor to the Company pursuant to Article V hereof;

 

(d)                                 to make any change that would provide any additional rights or benefits to the Holders of all or any Series of Notes or that does not adversely affect the rights hereunder of any Holder;

 

(e)                                  to comply with requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA;

 

(f)                                   to provide for the issuance of and establish the form and terms and conditions of Notes of any Series as permitted by this Indenture;

 

(g)                                  to add guarantees with respect to the Notes of any Series or to provide security for the Notes of any Series; or

 

(h)                                 to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Notes of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee.

 

Upon the request of the Company accompanied by a Board Resolution authorizing the execution of any such amended or supplemental indenture, and upon receipt by the Trustee of the documents described in Section 7.02 hereof, the Trustee will join with the Company in the execution of any amended or supplemental indenture authorized or permitted by the terms of this Indenture and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee will not be obligated to enter into such amended or supplemental indenture that affects its own rights, duties or immunities under this Indenture or otherwise.

 

Section 9.02                                                With Consent of Holders of Notes.  The Company and the Trustee may enter into a supplemental indenture with the written consent of the Holders of at least a majority in aggregate principal amount of the outstanding Notes of each Series affected by such supplemental indenture (including consents obtained in connection with a tender offer or exchange offer for the Notes of such Series), for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the Holders of Notes of each such Series.  Except as otherwise provided herein, the Holders of at least a majority in aggregate principal amount of the outstanding Notes of each Series affected thereby, by notice to the Trustee (including consents obtained in connection with a tender offer or exchange offer for the Notes of such Series) may waive compliance by the Company with any provision of this Indenture or the Notes with respect to such Series.

 

It shall not be necessary for the consent of the Holders of Notes of any Series under this Section 9.02 to approve the particular form of any proposed supplemental indenture or waiver, but it shall be sufficient if such consent approves the substance thereof.  Upon the request of the Company accompanied by a resolution of its Board of Directors authorizing the execution of any such amended or supplemental indenture, and upon the filing with the Trustee of evidence satisfactory to the Trustee of the consent of the Holders of Notes of such Series as aforesaid, and

 

37

 

upon receipt by the Trustee of the documents described in Section 7.02 hereof, the Trustee will join with the Company in the execution of such amended or supplemental indenture unless such amended or supplemental indenture directly affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion, but will not be obligated to, enter into such amended or supplemental Indenture.

 

After a supplemental indenture or waiver under this section becomes effective, the Company shall mail to the Holders of Notes of each Series affected thereby a notice briefly describing the supplemental indenture or waiver.  Any failure by the Company to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture or waiver.  However, without the consent of each Holder affected, an amendment or waiver under this Section 9.02 may not, with respect to any Notes of such Series held by a non-consenting Holder of each Series affected thereby:

 

(a)                                 reduce the principal amount, any premium or change the Stated Maturity of any Note or alter or waive any of the provisions with respect to the redemption or repurchase of the Notes;

 

(b)                                 reduce the rate (or alter the method of computation) of or extend the time for payment of interest, including defaulted interest, on any Note;

 

(c)                                  waive a Default or Event of Default in the payment of principal of or premium, if any, or interest on the Notes, except a rescission of acceleration of the Notes by the Holders of at least a majority in aggregate principal amount of the then outstanding Notes of such Series with respect to a nonpayment default and a waiver of the payment default that resulted from such acceleration;

 

(d)                                 make the principal of or premium, if any or interest on any Note payable in currency other than that stated in the Notes;

 

(e)                                  change any place of payment where the Notes of any series or interest thereon is payable;

 

(f)                                   make any change in the provisions of this Indenture relating to waivers of past Defaults or the rights of Holders of the Notes to receive payments of principal of or premium, interest, if any, on the Notes and to institute suit for the enforcement of any such payments;

 

(g)                                  make any change in the foregoing amendment and waiver provisions; or

 

(h)                                 reduce the percentage in principal amount of any Notes, the consent of the Holders of which is required for any of the foregoing modifications or otherwise necessary to modify or amend the Indenture or to waive any past Defaults.

 

Section 9.03                                                Compliance with Trust Indenture Act.  Every amendment to this Indenture or the Notes of one or more Series will be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.

 

38

 

Section 9.04                                                Revocation and Effect of Consents.  Until an amendment or waiver becomes effective, a consent to it by a Holder of a Note is a continuing consent by the Holder of a Note and every subsequent Holder of a Note or portion of a Note that evidences the same debt as the consenting Holder’s Note, even if notation of the consent is not made on any Note.  However, any such Holder of a Note or subsequent Holder of a Note may revoke the consent as to its Note if the Trustee receives written notice of revocation before the date the amendment or waiver becomes effective.  An amendment or waiver becomes effective in accordance with its terms and thereafter binds every Holder.

 

Section 9.05                                                Notation on or Exchange of Notes.  The Trustee may place an appropriate notation about an amendment or waiver on any Note of any Series thereafter authenticated.  The Company in exchange for Notes of that Series may issue and the Trustee shall authenticate upon request new Notes of that Series that reflect the amendment or waiver.

 

Failure to make the appropriate notation or issue a new Note will not affect the validity and effect of such amendment or waiver.

 

Section 9.06                                                Trustee to Sign Amendments, etc.  In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Section 7.01) shall be fully protected in relying upon, an Officer’s Certificate and an Opinion of Counsel stating that the execution of such supplemental indenture is authorized or permitted by this Indenture, and an Opinion of Counsel stating that it will be the legal, valid and binding upon the Company in accordance with its terms, subject to customary exceptions.  The Trustee shall sign all supplemental indentures, except that the Trustee need not sign any supplemental indenture that adversely affects its rights.

 

ARTICLE X

 

SATISFACTION AND DISCHARGE

 

Section 10.01                                         Satisfaction and Discharge.  This Indenture will be discharged and will cease to be of further effect as to a Series of Notes issued hereunder, when:

 

(a)                                 either:

 

(1)                                 all such Notes that have been authenticated, except lost, stolen or destroyed Notes that have been replaced or paid and Notes for whose payment money has theretofore been deposited in trust and thereafter repaid to the Company, have been delivered to the Trustee for cancellation; or

 

(2)                                 all such Notes that have not been delivered to the Trustee for cancellation have become due and payable by reason of the sending of a notice of redemption or otherwise or will become due and payable within one year and the Company has irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust solely for the benefit of the Holders of such Notes, cash in U.S. dollars, non-callable Government Securities, or a combination thereof, in such amounts as will be sufficient, without consideration of any investment of interest, in the written opinion of a nationally recognized investment bank, appraisal firm, or firm

 

39

 

of independent public accountants delivered to the Trustee, to pay and discharge the entire Indebtedness on the Notes not delivered to the Trustee for cancellation for principal, premium, if any, and accrued interest to the date of maturity or redemption;

 

(b)                                 no Default or Event of Default has occurred and is continuing on the date of such deposit (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit) and the deposit will not result in a breach or violation of, or constitute a default under, any other material instrument to which the Company or any guarantor, as applicable, is a party or by which the Company, or any guarantor, as applicable, is bound;

 

(c)                                  the Company or any guarantor of such Notes has paid or caused to be paid all sums payable by it under this Indenture; and

 

(d)                                 the Company has delivered irrevocable instructions to the Trustee under this Indenture to apply the deposited money toward the payment of the Notes at maturity or on the redemption date, as the case may be.

 

In addition, the Company must deliver an Officer’s Certificate and an Opinion of Counsel to the Trustee stating that all conditions precedent to satisfaction and discharge have been complied with.

 

Notwithstanding the satisfaction and discharge of this Indenture, if money has been deposited with the Trustee pursuant to subclause (2) of clause (a) of this Section 10.01, the provisions of Sections 10.02 and 8.06 hereof will survive.  In addition, nothing in this Section 10.01 will be deemed to discharge those provisions of Section 7.07 hereof, that, by their terms, survive the satisfaction and discharge of this Indenture.  After the conditions to discharge contained in this Article X have been satisfied, and the Company has paid or caused to be paid all other sums payable hereunder by the Company, and delivered to the Trustee an Officer’s Certificate and Opinion of Counsel, each stating that all conditions precedent to satisfaction and discharge have been complied with, the Trustee upon Company request shall acknowledge in writing the discharge of the obligations of the Company (except for those surviving obligations specified in this Section 10.01 and the rights, powers, trusts, duties and immunities of the Trustee hereunder and the Company’s obligations in connection therewith).

 

Section 10.02                                         Application of Trust Money.  Subject to the provisions of Section 8.06 hereof, all money deposited with the Trustee pursuant to Section 10.01 hereof shall be held in trust and applied by it, in accordance with the provisions of the Notes with respect to which such deposit was made and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its own Paying Agent) as the Trustee may determine, to the Persons entitled thereto, of the principal (and premium, if any) and interest for whose payment such money has been deposited with the Trustee; but such money need not be segregated from other funds except to the extent required by law.

 

If the Trustee or Paying Agent is unable to apply any money or Government Securities in accordance with Section 10.01 hereof by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the Company’s and any applicable guarantor’s obligations under

 

40

 

this Indenture and the applicable Notes shall be revived and reinstated as though no deposit had occurred pursuant to Section 10.01 hereof; provided that if the Company has made any payment of principal of, premium, if any, or interest on, any Notes because of the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Notes to receive such payment from the money or Government Securities held by the Trustee or Paying Agent.

 

ARTICLE XI

 

MISCELLANEOUS

 

Section 11.01                                         Trust Indenture Act Controls.  If any provision of this Indenture limits, qualifies or conflicts with another provision hereof which is required or deemed to be included in an indenture qualified under the TIA, such required or deemed to be included provision will control.

 

Section 11.02                                         Notices.  Any notice or communication by the Company or the Trustee to the others is duly given if in writing and delivered in Person or by first class mail (registered or certified, return receipt requested), facsimile transmission or overnight air courier guaranteeing next day delivery, to the others’ address:

 

If to the Company:

 

Spirit AeroSystems, Inc.
  Attention:  SVP General Counsel
 3801 South Oliver
 Wichita, KS 67210
 Facsimile No.:  (316)-529-4539

 

With a copy to (which copy shall be delivered as an accommodation and shall not be required to be delivered in satisfaction of any requirement hereof):

 

Sullivan & Cromwell LLP
 125 Broad Street
 New York, NY 10004
 Attention:  Robert W. Downes
 Facsimile No.:  (212) 558-3588

 

If to the Trustee:

 

The Bank of New York Mellon Trust Company, N.A.
 Attention:  Corporate Trust Office
 2 North LaSalle Street, 7th Floor
 Chicago, Illinois  60602
 Facsimile No.:  (312) 827-8542

 

The Company or the Trustee, by notice to the others, may designate additional or different addresses for subsequent notices or communications.

 

41

 

All notices and communications (other than those sent to Holders) will be deemed to have been duly given: at the time delivered by hand, if personally delivered; five Business Days after being deposited in the mail, postage prepaid, if mailed; when receipt acknowledged, if transmitted by facsimile; and the next Business Day after timely delivery to the courier, if sent by overnight air courier guaranteeing next day delivery.

 

Any notice or communication to a Holder will be mailed by first class mail, certified or registered, return receipt requested, or by overnight air courier guaranteeing next day delivery to its address shown on the register kept by the Registrar.  Any notice or communication will also be so mailed to any Person described in TIA § 313(c), to the extent required by the TIA.  Failure to mail a notice or communication to a Holder or any defect in it will not affect its sufficiency with respect to other Holders.  Notwithstanding any other provision of this Indenture or any Global Note, where this Indenture or any Global Note provides for notice of any event (including any notice of redemption or repurchase) to a Holder of a Global Note (whether by mail or otherwise), such notice shall be sufficiently given if given to the Depositary (or its designee) pursuant to the Applicable Procedures, including by electronic mail in accordance with the standing instructions from the Depositary.

 

If a notice or communication is mailed in the manner provided above within the time prescribed, it is duly given, whether or not the addressee receives it.

 

If the Company mails a notice or communication to Holders, it will mail a copy to the Trustee and each Agent at the same time.

 

The Trustee agrees to accept and act upon instructions or directions pursuant to this Indenture sent by unsecured e-mail, pdf, facsimile transmission or other similar unsecured electronic methods; provided, however, that (a) the party providing such written instructions, subsequent to such transmission of written instructions, shall provide the originally executed instructions or directions to the Trustee in a timely manner, and (b) such originally executed instructions or directions shall be signed by an authorized representative of the party providing such instructions or directions.  If the party elects to give the Trustee e-mail or facsimile instructions (or instructions by a similar electronic method) and the Trustee in its discretion elects to act upon such instructions, the Trustee’s understanding of such instructions shall be deemed controlling.  The Trustee shall not be liable for any losses, costs or expenses arising directly or indirectly from the Trustee’s reliance upon and compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction.  The party providing electronic instructions agrees to assume all risks arising out of the use of such electronic methods to submit instructions and directions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions, and the risk or interception and misuse by third parties.

 

Section 11.03                                         Communication by Holders of Notes with Other Holders of Notes.  Holders may communicate pursuant to TIA § 312(b) with other Holders with respect to their rights under this Indenture or the Notes.  The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA § 312(c).

 

42

 

Section 11.04                                         Certificate and Opinion as to Conditions Precedent.  Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee (except that in the case of any such application or request as to which the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application or request, no additional certificate or opinion need be furnished):

 

(1)                                 an Officer’s Certificate stating that, in the opinion of the signers (who may rely upon an Opinion of Counsel as to matters of law), all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and

 

(2)                                 an Opinion of Counsel stating that, in the opinion of such counsel (who may rely upon an Officer’s Certificate as to matters of fact), all such conditions precedent and covenants have been complied with.

 

Section 11.05                                         Statements Required in Certificate or Opinion.  Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to TIA § 314(a)(4)) must comply with the provisions of TIA § 314(e) and must include:

 

(1)                                 a statement that the Person making such certificate or opinion has read such covenant or condition;

 

(2)                                 a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;

 

(3)                                 a statement that, in the opinion of such Person, he or she has made such examination or investigation as is necessary to enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and

 

(4)                                 a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied with.

 

Section 11.06                                         Rules by Trustee and Agents.  Holders may make reasonable rules for action by or at a meeting of Holders.  The Registrar or Paying Agent may make reasonable rules and set reasonable requirements for its functions.

 

Section 11.07                                         Calculation of Foreign Currency Amounts.  The calculation of the U.S. dollar equivalent amount for any amount denominated in a foreign currency shall be the noon buying rate in the City of New York as certified by the Federal Reserve Bank of New York on the date on which such determination is required to be made or, if such day is not a day on which such rate is published, the rate most recently published prior to such day.

 

Section 11.08                                         No Personal Liability of Directors, Officers, Employees and Shareholders.  No past, present or future director, officer, employee, incorporator or shareholder of the Company, as such, will have any liability for any obligations of the Company under the Notes, this Indenture or for any claim based on, in respect of, or by reason of, such obligations or

 

43

 

their creation.  Each Holder of Notes by accepting a Note waives and releases all such liability.  The waiver and release are part of the consideration for issuance of the Notes.  The waiver may not be effective to waive liabilities under the federal securities laws.

 

Section 11.09                                         Governing Law; Submission to Jurisdiction.  THE LAWS OF THE STATE OF NEW YORK WILL GOVERN AND BE USED TO CONSTRUE THIS INDENTURE, THE NOTES, AND THE GUARANTEES, IF ANY, WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.  Each of the parties hereto agrees that any legal action or proceeding with respect to or arising out of this Indenture may be brought in or removed to the courts of the State of New York or of the United States of America, in each case located in the borough of Manhattan, the City of New York.  By execution and delivery of this Indenture, each of the parties hereto accepts, for themselves and in respect of their property, generally and unconditionally, the non-exclusive jurisdiction of the aforesaid courts.  Each of the parties hereto irrevocably consents to the service of process out of any of the aforementioned courts in any manner permitted by law.  Nothing herein shall affect the right of any party to bring legal action or proceedings in any other competent jurisdiction.  Each of the parties hereto hereby waives any right to stay or dismiss any action or proceeding under or in connection with this Indenture brought before the foregoing courts on the basis of forum non-conveniens.

 

Section 11.10                                         No Adverse Interpretation of Other Agreements.  This Indenture may not be used to interpret any other indenture, loan or debt agreement of the Company or its Subsidiaries or of any other Person.  Any such indenture, loan or debt agreement may not be used to interpret this Indenture.

 

Section 11.11                                         Successors.  All agreements of the Company in this Indenture and the Notes will bind its successors.  All agreements of the Trustee in this Indenture will bind its successors.

 

Section 11.12                                         Severability.  In case any provision in this Indenture or in the Notes is invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.

 

Section 11.13                                         Counterpart Originals.  The parties may sign any number of copies of this Indenture.  Each signed copy will be an original, but all of them together represent the same agreement.  The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

 

Section 11.14                                         Table of Contents, Headings, etc.  The Table of Contents, Cross-Reference Table and Headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part of this Indenture and will in no way modify or restrict any of the terms or provisions hereof.

 

44

 

Section 11.15                                         Waiver of Jury Trial.  EACH OF THE COMPANY AND THE TRUSTEE, AND EACH HOLDER OF A NOTE BY ITS ACCEPTANCE THEREOF, HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

Section 11.16                                         Patriot Act Compliance.  The parties hereto acknowledge that in accordance with Section 326 of the USA Patriot Act the Trustee, like all financial institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account, which information includes the name, address, tax identification number and formation documents and other information that will allow Trustee to identify the person or legal entity in accordance with the USA Patriot Act.  The parties to this Agreement agree that they will provide the Trustee with such information in order for the Trustee to satisfy the requirements of the USA Patriot Act.

 

[Signatures on following page]

 

45

 

SIGNATURES

 

	
Dated   as of [  ], 2019
    	
 
    
	
 
    	
 
    
	
 
    	
SPIRIT   AEROSYSTEMS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
THE   BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    

 

46

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]